{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "name": "Matching_Top10Percent_DrugLabelsandPatent.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "machine_shape": "hm"
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "tPeuSU3LjBza"
      },
      "source": [
        "This sheets answers the question of: out of the best models, how similar are the top X% of the results.  The best models are mpnet_base_v2, roberta, and scispacy, since all three of these models have the greatest z-scores from the noise.  See Noise_to_Related_Claims_Histogram_DrugLabelsandPatent.ipynb."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6JDsiezRUEQY",
        "outputId": "a3eadde1-3718-4507-cc22-2073817e8e22"
      },
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive', force_remount=True)\n",
        "zip_path='/content/drive/MyDrive/Colab Notebooks/zip/db2file.zip'\n",
        "!cp \"{zip_path}\" .\n",
        "!cp \"/content/drive/MyDrive/Colab Notebooks/requirements.txt\" .\n",
        "!unzip -q db2file.zip\n",
        "!rm db2file.zip\n",
        "!rm -r en_core_sci_lg-0.4.0.zip\n",
        "!cp \"/content/drive/MyDrive/Colab Notebooks/zip/en_core_sci_lg-0.4.0.zip\" .\n",
        "!unzip -q en_core_sci_lg-0.4.0.zip\n",
        "!rm en_core_sci_lg-0.4.0.zip"
      ],
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mounted at /content/drive\n",
            "replace db2file/10402/87E2DA8D-432C-4ED5-67A1-DC26294B2295/additions_with_context/2007-08-27? [y]es, [n]o, [A]ll, [N]one, [r]ename: A\n",
            "rm: cannot remove 'en_core_sci_lg-0.4.0.zip': No such file or directory\n",
            "replace en_core_sci_lg-0.4.0/MANIFEST.in? [y]es, [n]o, [A]ll, [N]one, [r]ename: A\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wmH958tXWkKh",
        "outputId": "453b8330-dafc-47f9-ea4c-b7249319789e"
      },
      "source": [
        "!pip install -r '/content/requirements.txt'"
      ],
      "execution_count": 86,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: beautifulsoup4==4.9.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 1)) (4.9.3)\n",
            "Requirement already satisfied: blis==0.7.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 2)) (0.7.4)\n",
            "Requirement already satisfied: catalogue==2.0.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 3)) (2.0.4)\n",
            "Requirement already satisfied: certifi==2020.12.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 4)) (2020.12.5)\n",
            "Requirement already satisfied: chardet==4.0.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 5)) (4.0.0)\n",
            "Requirement already satisfied: click==7.1.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 6)) (7.1.2)\n",
            "Requirement already satisfied: conllu==4.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 7)) (4.4)\n",
            "Requirement already satisfied: cymem==2.0.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 8)) (2.0.5)\n",
            "Requirement already satisfied: diff-match-patch==20200713 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 9)) (20200713)\n",
            "Requirement already satisfied: filelock==3.0.12 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 10)) (3.0.12)\n",
            "Requirement already satisfied: ftfy==5.9 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 11)) (5.9)\n",
            "Requirement already satisfied: idna==2.10 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 12)) (2.10)\n",
            "Requirement already satisfied: Jinja2==2.11.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 13)) (2.11.3)\n",
            "Requirement already satisfied: joblib==1.0.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 14)) (1.0.1)\n",
            "Requirement already satisfied: lxml==4.6.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 15)) (4.6.3)\n",
            "Requirement already satisfied: MarkupSafe==1.1.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 16)) (1.1.1)\n",
            "Requirement already satisfied: murmurhash==1.0.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 17)) (1.0.5)\n",
            "Requirement already satisfied: nltk==3.6.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 18)) (3.6.2)\n",
            "Requirement already satisfied: nmslib==2.1.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 19)) (2.1.1)\n",
            "Requirement already satisfied: numpy==1.20.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 20)) (1.20.2)\n",
            "Requirement already satisfied: packaging==20.9 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 21)) (20.9)\n",
            "Requirement already satisfied: pandas==1.2.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 22)) (1.2.4)\n",
            "Requirement already satisfied: pathy==0.5.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 23)) (0.5.2)\n",
            "Requirement already satisfied: preshed==3.0.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 24)) (3.0.5)\n",
            "Requirement already satisfied: psutil==5.8.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 25)) (5.8.0)\n",
            "Requirement already satisfied: pybind11==2.6.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 26)) (2.6.1)\n",
            "Requirement already satisfied: pydantic==1.7.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 27)) (1.7.3)\n",
            "Requirement already satisfied: pymongo==3.11.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 28)) (3.11.3)\n",
            "Requirement already satisfied: pyparsing==2.4.7 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 29)) (2.4.7)\n",
            "Requirement already satisfied: pysbd==0.3.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 30)) (0.3.4)\n",
            "Requirement already satisfied: python-dateutil==2.8.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 31)) (2.8.1)\n",
            "Requirement already satisfied: python-dotenv==0.16.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 32)) (0.16.0)\n",
            "Requirement already satisfied: pytz==2021.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 33)) (2021.1)\n",
            "Requirement already satisfied: regex==2021.4.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 34)) (2021.4.4)\n",
            "Requirement already satisfied: requests==2.25.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 35)) (2.25.1)\n",
            "Requirement already satisfied: sacremoses==0.0.45 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 36)) (0.0.45)\n",
            "Requirement already satisfied: scikit-learn==0.24.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 37)) (0.24.2)\n",
            "Requirement already satisfied: scipy==1.6.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 38)) (1.6.3)\n",
            "Requirement already satisfied: scispacy==0.4.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 39)) (0.4.0)\n",
            "Requirement already satisfied: sentence-transformers==1.1.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 40)) (1.1.0)\n",
            "Requirement already satisfied: sentencepiece==0.1.95 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 41)) (0.1.95)\n",
            "Requirement already satisfied: six==1.15.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 42)) (1.15.0)\n",
            "Requirement already satisfied: sklearn==0.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 43)) (0.0)\n",
            "Requirement already satisfied: smart-open==3.0.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 44)) (3.0.0)\n",
            "Requirement already satisfied: soupsieve==2.2.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 45)) (2.2.1)\n",
            "Requirement already satisfied: spacy==3.0.6 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 46)) (3.0.6)\n",
            "Requirement already satisfied: spacy-alignments==0.8.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 47)) (0.8.3)\n",
            "Requirement already satisfied: spacy-legacy==3.0.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 48)) (3.0.5)\n",
            "Requirement already satisfied: spacy-transformers==1.0.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 49)) (1.0.2)\n",
            "Requirement already satisfied: srsly==2.4.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 50)) (2.4.1)\n",
            "Requirement already satisfied: thinc==8.0.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 51)) (8.0.3)\n",
            "Requirement already satisfied: threadpoolctl==2.1.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 52)) (2.1.0)\n",
            "Requirement already satisfied: tokenizers==0.10.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 53)) (0.10.2)\n",
            "Requirement already satisfied: torch==1.8.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 54)) (1.8.1+cu101)\n",
            "Requirement already satisfied: torchcontrib==0.0.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 55)) (0.0.2)\n",
            "Requirement already satisfied: tqdm==4.60.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 56)) (4.60.0)\n",
            "Requirement already satisfied: transformers==4.5.1 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 57)) (4.5.1)\n",
            "Requirement already satisfied: typer==0.3.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 58)) (0.3.2)\n",
            "Requirement already satisfied: typing-extensions==3.7.4.3 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 59)) (3.7.4.3)\n",
            "Requirement already satisfied: urllib3==1.26.4 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 60)) (1.26.4)\n",
            "Requirement already satisfied: wasabi==0.8.2 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 61)) (0.8.2)\n",
            "Requirement already satisfied: wcwidth==0.2.5 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 62)) (0.2.5)\n",
            "Requirement already satisfied: xmltodict==0.12.0 in /usr/local/lib/python3.7/dist-packages (from -r /content/requirements.txt (line 63)) (0.12.0)\n",
            "Requirement already satisfied: zipp>=0.5; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from catalogue==2.0.4->-r /content/requirements.txt (line 3)) (3.4.1)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy==3.0.6->-r /content/requirements.txt (line 46)) (56.0.0)\n",
            "Requirement already satisfied: importlib-metadata; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from transformers==4.5.1->-r /content/requirements.txt (line 57)) (3.10.1)\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "mcAlDL4NXGWL"
      },
      "source": [
        "import random\n",
        "import os\n",
        "random.seed(30)\n",
        "db2files = \"/content/db2file/\"\n",
        "NDA_list=[f for f in os.listdir(db2files)]"
      ],
      "execution_count": 87,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "mBDg-2lZg50N"
      },
      "source": [
        "def get_lines_in_file(file_name):\n",
        "  if os.path.exists(file_name):\n",
        "    f = open(file_name, \"rb\")\n",
        "    return_list = [str(line.decode('unicode_escape')) for line in f if line.decode('unicode_escape').strip()]\n",
        "    f.close()\n",
        "    return return_list\n",
        "  else:\n",
        "    return []"
      ],
      "execution_count": 88,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "XqZgsrZj9SUO"
      },
      "source": [
        "def flat_list(lst):\n",
        "  return [item for sublist in lst for item in sublist]\n",
        "\n",
        "def get_additions(NDA, additions_folder_name):\n",
        "  \"\"\" \n",
        "  Return all additions as a list for the set-id with most additions for a NDA \n",
        "  excluding the first addition.\n",
        "  Parameters:\n",
        "      NDA (string): NDA dir\n",
        "      additions_folder_name (string): either 'just_additions' or 'additions_with_context'\n",
        "  \"\"\"\n",
        "  if additions_folder_name not in ['just_additions', 'additions_with_context']:\n",
        "    print(f\"Parameter {additions_folder_name} not in ['just_additions', 'additions_with_context']\")\n",
        "    return []\n",
        "  NDA_dir=db2files+str(NDA)+'/'\n",
        "  set_id_dirs=[f for f in os.listdir(NDA_dir)]\n",
        "  try:\n",
        "    set_id_dirs.remove('patents')\n",
        "  except ValueError:\n",
        "    pass\n",
        "  additions_list=[]\n",
        "  for set_id_dir in set_id_dirs:\n",
        "    additions_dir=NDA_dir+set_id_dir+'/'+additions_folder_name+'/'\n",
        "    if os.path.exists(additions_dir):\n",
        "      additions_files=sorted([additions_dir+f for f in os.listdir(additions_dir)])[1:]\n",
        "      additions_list_tmp=flat_list([get_lines_in_file(file) for file in additions_files])\n",
        "      if len(additions_list_tmp)> len(additions_list):\n",
        "        additions_list=additions_list_tmp\n",
        "  return additions_list\n",
        "\n",
        "def get_patent_claims(NDA, patents_folder_name):\n",
        "  \"\"\"Return a list of patents claims for a NDA\n",
        "  Parameters:\n",
        "      NDA (string): NDA dir\n",
        "      patents_folder_name (string): either 'patents' or 'patents_longhand'\n",
        "  \"\"\"\n",
        "  patent_dir=db2files+str(NDA)+'/'+patents_folder_name+'/'\n",
        "  if os.path.exists(patent_dir):\n",
        "    patent_files=[patent_dir+f for f in os.listdir(patent_dir)]\n",
        "    return flat_list([get_lines_in_file(file) for file in patent_files])\n",
        "  return []\n",
        "    "
      ],
      "execution_count": 89,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rH_rqHMEpbnm",
        "outputId": "c6686448-bd72-4167-be6d-4e6f33996759"
      },
      "source": [
        "random_NDA_list=random.sample(NDA_list, int(len(NDA_list)*.33))\n",
        "print(len(NDA_list), len(random_NDA_list), random_NDA_list[1])"
      ],
      "execution_count": 90,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "1606 529 202895-21976\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "yIG3xW2C5Suc"
      },
      "source": [
        "# narrow 1/3 of random data to NDA with patents and NDAs with additions.  If either is missing, we cannot check quality of additions to related patents.\n",
        "random_NDA_list=[x for x in random_NDA_list if get_patent_claims(x, 'patents') and get_additions(x, 'additions_with_context')]"
      ],
      "execution_count": 91,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hFuJ6ViNIAVU",
        "outputId": "7a1883ae-fbeb-434f-9a86-a26b3faff52c"
      },
      "source": [
        "print(len(random_NDA_list))"
      ],
      "execution_count": 92,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "292\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "XNvnVArssTah"
      },
      "source": [
        "def return_match(NDA, additions_folder_name, patent_folder_name, scoring_method_list, cutoff_percentage=.1):\n",
        "  \"\"\"\n",
        "  This method returns {(\"method_name\", NDA, len(additions), len(claims)):[[claim_num, claim_num],],}\n",
        "  Parameters:\n",
        "    random_NDA_list (list): list of NDA numbers\n",
        "    additions_folder_name (string): either 'patents' or 'patents_longhand'\n",
        "    patent_folder_name (string): either 'just_additions' or 'additions_with_context'\n",
        "    scoring_method_list (list): list of [[function that is use to score similarity, optional_scoring_method_field],..]\n",
        "  \"\"\"\n",
        "\n",
        "  # scoring_method_result_dict={ \"scoring_method.__name__\": {\"additions_len\": X, \"claims_len\": X, \"matches\":[(addition, claim), }}\n",
        "  scoring_method_result_dict={}\n",
        "\n",
        "  for i in range(len(scoring_method_list)):\n",
        "    scoring_method=scoring_method_list[i][0]\n",
        "    optional_scoring_method_field=scoring_method_list[i][1]\n",
        "    optional_scoring_method_field_name=scoring_method_list[i][2]\n",
        "\n",
        "    claims = get_patent_claims(NDA, patent_folder_name)\n",
        "    additions = get_additions(NDA, additions_folder_name)\n",
        "\n",
        "    matrix=scoring_method(additions, claims, optional_scoring_method_field)\n",
        "    # get top 10 percent of each row/addition of the matrix.\n",
        "    top_10 = top_10_percent_matrix(matrix, cutoff_percentage)\n",
        "    method_name = optional_scoring_method_field_name if optional_scoring_method_field else scoring_method.__name__\n",
        "    key = (method_name, NDA, len(additions), len(claims))\n",
        "    scoring_method_result_dict[key]=top_10\n",
        "  return scoring_method_result_dict\n",
        "\n"
      ],
      "execution_count": 100,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "T1JlbMDr11Cl"
      },
      "source": [
        "import math\n",
        "def top_10_percent_matrix(matrix, cutoff_percentage):\n",
        "  \"\"\" Return a matrix: ie. [[claim_num_index, claim_num_index],] for top 10% of each match.\n",
        "        The rows represents additions.\n",
        "\n",
        "  Parameters:\n",
        "    matrix (list of list): a matrix where the rows represents additions, and the columns, claims for all additions to all claims\n",
        "  \"\"\"\n",
        "  return_matrix_of_index=[]\n",
        "  for row in matrix:\n",
        "    length_10percent=math.ceil(len(row)*cutoff_percentage)\n",
        "    # get indices of top 10 in max_scores_list\n",
        "    indexes=sorted(range(len(row)), key=lambda i: row[i], reverse=True)[:length_10percent]\n",
        "    return_matrix_of_index.append(indexes)\n",
        "  return return_matrix_of_index\n"
      ],
      "execution_count": 101,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "T621ChlOv3JN"
      },
      "source": [
        "from sentence_transformers import SentenceTransformer, util\n",
        "\n",
        "def scoring_method_bert(additions, claims, model):\n",
        "  \"\"\" Returns a list of [[cosine_score,cosine_score,],], where rows indicate addition, columns are claims.\n",
        "  \"\"\"\n",
        "  # Compute embedding for both lists\n",
        "  additions_embeddings = model.encode(\n",
        "      additions,\n",
        "      convert_to_tensor=True,\n",
        "  )\n",
        "  claims_embeddings = model.encode(\n",
        "      claims,\n",
        "      convert_to_tensor=True,\n",
        "  )\n",
        "  # Compute cosine-similarity for every additions to every claim\n",
        "  cosine_scores = util.pytorch_cos_sim(\n",
        "      additions_embeddings, claims_embeddings\n",
        "  ).tolist()\n",
        "  return cosine_scores\n"
      ],
      "execution_count": 102,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "T-yGTUILaIsI",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "555f43e8-b77b-4427-b75d-6b482c9a0c94"
      },
      "source": [
        "import spacy\n",
        "gpu = spacy.prefer_gpu()\n",
        "print('GPU:', gpu)\n",
        "!pip install -U spacy[cuda101]\n",
        "_N_PROCESS = 1\n",
        "_en_core_sci_lg_nlp = spacy.load(\"/content/en_core_sci_lg-0.4.0/en_core_sci_lg/en_core_sci_lg-0.4.0\")\n",
        "!python -m spacy download en_core_web_trf\n",
        "nlp_en = spacy.load('en_core_web_trf')"
      ],
      "execution_count": 96,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "GPU: True\n",
            "Requirement already up-to-date: spacy[cuda101] in /usr/local/lib/python3.7/dist-packages (3.0.6)\n",
            "Requirement already satisfied, skipping upgrade: srsly<3.0.0,>=2.4.1 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (2.4.1)\n",
            "Requirement already satisfied, skipping upgrade: catalogue<2.1.0,>=2.0.3 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (2.0.4)\n",
            "Requirement already satisfied, skipping upgrade: blis<0.8.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (0.7.4)\n",
            "Requirement already satisfied, skipping upgrade: numpy>=1.15.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (1.20.2)\n",
            "Requirement already satisfied, skipping upgrade: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (2.25.1)\n",
            "Requirement already satisfied, skipping upgrade: thinc<8.1.0,>=8.0.3 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (8.0.3)\n",
            "Requirement already satisfied, skipping upgrade: jinja2 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (2.11.3)\n",
            "Requirement already satisfied, skipping upgrade: packaging>=20.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (20.9)\n",
            "Requirement already satisfied, skipping upgrade: typer<0.4.0,>=0.3.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (0.3.2)\n",
            "Requirement already satisfied, skipping upgrade: spacy-legacy<3.1.0,>=3.0.4 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (3.0.5)\n",
            "Requirement already satisfied, skipping upgrade: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (1.0.5)\n",
            "Requirement already satisfied, skipping upgrade: pydantic<1.8.0,>=1.7.1 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (1.7.3)\n",
            "Requirement already satisfied, skipping upgrade: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (2.0.5)\n",
            "Requirement already satisfied, skipping upgrade: wasabi<1.1.0,>=0.8.1 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (0.8.2)\n",
            "Requirement already satisfied, skipping upgrade: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (4.60.0)\n",
            "Requirement already satisfied, skipping upgrade: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (3.0.5)\n",
            "Requirement already satisfied, skipping upgrade: typing-extensions<4.0.0.0,>=3.7.4; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (3.7.4.3)\n",
            "Requirement already satisfied, skipping upgrade: pathy>=0.3.5 in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (0.5.2)\n",
            "Requirement already satisfied, skipping upgrade: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (56.0.0)\n",
            "Requirement already satisfied, skipping upgrade: cupy-cuda101<9.0.0,>=5.0.0b4; extra == \"cuda101\" in /usr/local/lib/python3.7/dist-packages (from spacy[cuda101]) (7.4.0)\n",
            "Requirement already satisfied, skipping upgrade: zipp>=0.5; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from catalogue<2.1.0,>=2.0.3->spacy[cuda101]) (3.4.1)\n",
            "Requirement already satisfied, skipping upgrade: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy[cuda101]) (2.10)\n",
            "Requirement already satisfied, skipping upgrade: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy[cuda101]) (2020.12.5)\n",
            "Requirement already satisfied, skipping upgrade: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy[cuda101]) (1.26.4)\n",
            "Requirement already satisfied, skipping upgrade: chardet<5,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy[cuda101]) (4.0.0)\n",
            "Requirement already satisfied, skipping upgrade: MarkupSafe>=0.23 in /usr/local/lib/python3.7/dist-packages (from jinja2->spacy[cuda101]) (1.1.1)\n",
            "Requirement already satisfied, skipping upgrade: pyparsing>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from packaging>=20.0->spacy[cuda101]) (2.4.7)\n",
            "Requirement already satisfied, skipping upgrade: click<7.2.0,>=7.1.1 in /usr/local/lib/python3.7/dist-packages (from typer<0.4.0,>=0.3.0->spacy[cuda101]) (7.1.2)\n",
            "Requirement already satisfied, skipping upgrade: smart-open<4.0.0,>=2.2.0 in /usr/local/lib/python3.7/dist-packages (from pathy>=0.3.5->spacy[cuda101]) (3.0.0)\n",
            "Requirement already satisfied, skipping upgrade: six>=1.9.0 in /usr/local/lib/python3.7/dist-packages (from cupy-cuda101<9.0.0,>=5.0.0b4; extra == \"cuda101\"->spacy[cuda101]) (1.15.0)\n",
            "Requirement already satisfied, skipping upgrade: fastrlock>=0.3 in /usr/local/lib/python3.7/dist-packages (from cupy-cuda101<9.0.0,>=5.0.0b4; extra == \"cuda101\"->spacy[cuda101]) (0.6)\n",
            "2021-05-06 02:04:12.501568: I tensorflow/stream_executor/platform/default/dso_loader.cc:49] Successfully opened dynamic library libcudart.so.11.0\n",
            "Requirement already satisfied: en-core-web-trf==3.0.0 from https://github.com/explosion/spacy-models/releases/download/en_core_web_trf-3.0.0/en_core_web_trf-3.0.0-py3-none-any.whl#egg=en_core_web_trf==3.0.0 in /usr/local/lib/python3.7/dist-packages (3.0.0)\n",
            "Requirement already satisfied: spacy<3.1.0,>=3.0.0 in /usr/local/lib/python3.7/dist-packages (from en-core-web-trf==3.0.0) (3.0.6)\n",
            "Requirement already satisfied: spacy-transformers<1.1.0,>=1.0.0rc4 in /usr/local/lib/python3.7/dist-packages (from en-core-web-trf==3.0.0) (1.0.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (20.9)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.25.1)\n",
            "Requirement already satisfied: pydantic<1.8.0,>=1.7.1 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (1.7.3)\n",
            "Requirement already satisfied: thinc<8.1.0,>=8.0.3 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (8.0.3)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (56.0.0)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.4 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (3.0.5)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.11.3)\n",
            "Requirement already satisfied: pathy>=0.3.5 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (0.5.2)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (3.0.5)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (0.7.4)\n",
            "Requirement already satisfied: typing-extensions<4.0.0.0,>=3.7.4; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (3.7.4.3)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.1 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.4.1)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (4.60.0)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.0.5)\n",
            "Requirement already satisfied: numpy>=1.15.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (1.20.2)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (1.0.5)\n",
            "Requirement already satisfied: wasabi<1.1.0,>=0.8.1 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (0.8.2)\n",
            "Requirement already satisfied: typer<0.4.0,>=0.3.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (0.3.2)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.3 in /usr/local/lib/python3.7/dist-packages (from spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.0.4)\n",
            "Requirement already satisfied: spacy-alignments<1.0.0,>=0.7.2 in /usr/local/lib/python3.7/dist-packages (from spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (0.8.3)\n",
            "Requirement already satisfied: transformers<4.6.0,>=3.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (4.5.1)\n",
            "Requirement already satisfied: torch>=1.5.0 in /usr/local/lib/python3.7/dist-packages (from spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (1.8.1+cu101)\n",
            "Requirement already satisfied: pyparsing>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from packaging>=20.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.4.7)\n",
            "Requirement already satisfied: chardet<5,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (4.0.0)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2.10)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (2020.12.5)\n",
            "Requirement already satisfied: urllib3<1.27,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (1.26.4)\n",
            "Requirement already satisfied: MarkupSafe>=0.23 in /usr/local/lib/python3.7/dist-packages (from jinja2->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (1.1.1)\n",
            "Requirement already satisfied: smart-open<4.0.0,>=2.2.0 in /usr/local/lib/python3.7/dist-packages (from pathy>=0.3.5->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (3.0.0)\n",
            "Requirement already satisfied: click<7.2.0,>=7.1.1 in /usr/local/lib/python3.7/dist-packages (from typer<0.4.0,>=0.3.0->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (7.1.2)\n",
            "Requirement already satisfied: zipp>=0.5; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from catalogue<2.1.0,>=2.0.3->spacy<3.1.0,>=3.0.0->en-core-web-trf==3.0.0) (3.4.1)\n",
            "Requirement already satisfied: tokenizers<0.11,>=0.10.1 in /usr/local/lib/python3.7/dist-packages (from transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (0.10.2)\n",
            "Requirement already satisfied: sacremoses in /usr/local/lib/python3.7/dist-packages (from transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (0.0.45)\n",
            "Requirement already satisfied: importlib-metadata; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (3.10.1)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.7/dist-packages (from transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (2021.4.4)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.7/dist-packages (from transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (3.0.12)\n",
            "Requirement already satisfied: six in /usr/local/lib/python3.7/dist-packages (from sacremoses->transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (1.15.0)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.7/dist-packages (from sacremoses->transformers<4.6.0,>=3.4.0->spacy-transformers<1.1.0,>=1.0.0rc4->en-core-web-trf==3.0.0) (1.0.1)\n",
            "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
            "You can now load the package via spacy.load('en_core_web_trf')\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "xTyvGYJx6DNU"
      },
      "source": [
        "\n",
        "def preprocess_with_spacy_nlp(text_list, steps, nlp=nlp_en):\n",
        "    \"\"\"\n",
        "    This method can remove punctuation,\n",
        "    Parameters:\n",
        "        text_list (list): list of strings\n",
        "        steps (list): one of [\"punct\", \"lemma\", \"stopwords\"]\n",
        "    \"\"\"\n",
        "    # make a copy of text_lis\n",
        "    return_list = text_list\n",
        "    if any(item in [\"punct\", \"lemma\", \"stopwords\"] for item in steps):\n",
        "        # 'lemmatizer' required 'tagger' and 'attribute_ruler'\n",
        "        nlp_list = list(\n",
        "            nlp.pipe(\n",
        "                return_list,\n",
        "                disable=[\"tok2vec\", \"ner\"],\n",
        "                n_process=_N_PROCESS,\n",
        "            )\n",
        "        )\n",
        "        return_list = [\n",
        "            \" \".join(\n",
        "                [\n",
        "                    token.lemma_ if \"lemma\" in steps else token.text\n",
        "                    for token in doc\n",
        "                    if (\n",
        "                        (\n",
        "                            (\"punct\" in steps and not token.is_punct)\n",
        "                            or \"punct\" not in steps\n",
        "                        )\n",
        "                        and (\n",
        "                            (\"stopwords\" in steps and not token.is_stop)\n",
        "                            or \"stopwords\" not in steps\n",
        "                        )\n",
        "                    )\n",
        "                ]\n",
        "            )\n",
        "            for doc in nlp_list\n",
        "        ]\n",
        "    return return_list\n",
        "\n",
        "\n",
        "def similarity_matrix(embed_A_list, embed_B_list):\n",
        "    \"\"\"\n",
        "    This method returns a matrix such as:\n",
        "        [[X, X, X],\n",
        "        [X, X, X]]\n",
        "    wherein each row represents the similarity measurement between an embedding\n",
        "    from embed_A_list to each of the embeddings in embed_B_list.\n",
        "\n",
        "    Parameters:\n",
        "        embed_A_list (list): list of NLP object generated by spaCy\n",
        "        embed_B_list (list): list of NLP object generated by spaCy to be\n",
        "                             compared to embed_A\n",
        "    \"\"\"\n",
        "    matrix = [[0] * len(embed_B_list) for y in range(len(embed_A_list))]\n",
        "    for i in range(len(embed_A_list)):\n",
        "        for j in range(len(embed_B_list)):\n",
        "            matrix[i][j] = embed_A_list[i].similarity(embed_B_list[j])\n",
        "    return matrix\n",
        "\n",
        "\n",
        "def scoring_method_spacy(additions, claims, nlp=nlp_en):\n",
        "  \"\"\" Scores with spaCy; return a matrix of similar scores\n",
        "  \"\"\"\n",
        "  additions=preprocess_with_spacy_nlp(additions, [\"punct\", \"lemma\", \"stopwords\"], nlp)\n",
        "  claims=preprocess_with_spacy_nlp(claims, [\"punct\", \"lemma\", \"stopwords\"], nlp)\n",
        "  # Compute embedding for both lists\n",
        "  # tokenization only requires tok2vec\n",
        "  disabled_list = [\"tagger\", \"attribute_ruler\", \"lemmatizer\", \"parser\", \"ner\"]\n",
        "  additions_embeddings = list(\n",
        "      nlp.pipe(\n",
        "          additions, disable=disabled_list, n_process=_N_PROCESS\n",
        "      )\n",
        "  )\n",
        "  claims_embeddings = list(\n",
        "      nlp.pipe(\n",
        "          claims, disable=disabled_list, n_process=_N_PROCESS\n",
        "      )\n",
        "  )\n",
        "  # Compute cosine-similarity for every additions to every claim\n",
        "  return similarity_matrix(additions_embeddings, claims_embeddings)\n"
      ],
      "execution_count": 103,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "C8Aj-QY0EklL"
      },
      "source": [
        "_device = None\n",
        "\n",
        "model_mpnet_base_v2 = SentenceTransformer(\"stsb-mpnet-base-v2\", device=_device)\n",
        "model_mpnet_base_v2.zero_grad()\n",
        "# Will limit size since CUDA runs out of memory\n",
        "model_mpnet_base_v2.max_seq_length=512\n",
        "\n",
        "model_roberta_base_v2 = SentenceTransformer(\"stsb-roberta-base-v2\", device=_device)\n",
        "model_roberta_base_v2.zero_grad()\n",
        "# Will limit size since CUDA runs out of memory\n",
        "model_roberta_base_v2.max_seq_length=512\n",
        "\n"
      ],
      "execution_count": 104,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8C9qpkiKXcwS",
        "outputId": "02b5a759-2038-4693-88e6-7bad7401aae0"
      },
      "source": [
        "\n",
        "scoring_method_list=[\n",
        "                     [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert,model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     [scoring_method_spacy,nlp_en, \"en_core_web_trf\"],\n",
        "                     [scoring_method_spacy,_en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"],]\n",
        "\n",
        "NDA=random_NDA_list[3]\n",
        "\n",
        "# return_match_result={(\"method_name\", NDA, len(additions), len(claims)):[[claim_num, claim_num],],}, \n",
        "# where the value are (row) additions and (col) index/specific line in the patent file when all files are joined together\n",
        "return_match_result=return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1)\n",
        "print(return_match_result)\n"
      ],
      "execution_count": 105,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/ipykernel_launcher.py:58: UserWarning: [W007] The model you're using has no word vectors loaded, so the result of the Doc.similarity method will be based on the tagger, parser and NER, which may not give useful similarity judgements. This may happen if you're using one of the small models, e.g. `en_core_web_sm`, which don't ship with word vectors and only use context-sensitive tensors. You can always add your own word vectors, or use one of the larger models instead if available.\n",
            "/usr/local/lib/python3.7/dist-packages/ipykernel_launcher.py:58: UserWarning: [W008] Evaluating Doc.similarity based on empty vectors.\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "stream",
          "text": [
            "{('model_mpnet_base_v2', '208051', 8, 176): [[101, 112, 109, 164, 22, 142, 39, 51, 0, 114, 118, 110, 103, 175, 113, 115, 111, 159], [92, 78, 68, 65, 154, 79, 97, 64, 34, 91, 60, 70, 49, 81, 61, 87, 82, 50], [101, 112, 109, 142, 22, 164, 39, 51, 0, 114, 118, 115, 110, 175, 111, 103, 113, 159], [131, 91, 61, 65, 96, 86, 76, 31, 81, 23, 62, 119, 78, 35, 27, 82, 60, 85], [128, 129, 170, 130, 42, 138, 168, 167, 86, 87, 139, 26, 165, 140, 23, 35, 27, 55], [101, 109, 112, 22, 142, 39, 0, 164, 51, 110, 111, 114, 115, 175, 118, 75, 159, 73], [142, 0, 22, 109, 101, 39, 112, 164, 51, 175, 111, 114, 2, 144, 159, 75, 162, 143], [0, 142, 101, 112, 39, 109, 51, 22, 164, 175, 111, 114, 143, 75, 110, 35, 96, 159]], ('model_roberta_base_v2', '208051', 8, 176): [[101, 109, 112, 142, 118, 115, 0, 103, 22, 39, 51, 164, 75, 175, 117, 143, 59, 1], [87, 97, 92, 54, 82, 62, 84, 94, 52, 51, 99, 30, 55, 38, 59, 40, 53, 89], [101, 109, 142, 112, 118, 115, 0, 22, 103, 39, 164, 117, 51, 75, 143, 175, 116, 1], [119, 65, 87, 64, 82, 131, 92, 97, 174, 171, 170, 172, 78, 173, 79, 166, 165, 167], [128, 138, 140, 139, 129, 130, 73, 97, 127, 55, 119, 43, 84, 38, 26, 82, 32, 92], [101, 109, 142, 112, 0, 118, 115, 22, 39, 103, 51, 75, 164, 47, 59, 175, 117, 143], [142, 0, 101, 22, 109, 115, 118, 112, 39, 164, 51, 175, 75, 143, 117, 1, 103, 59], [142, 0, 101, 22, 39, 115, 109, 51, 118, 112, 175, 164, 143, 75, 117, 1, 103, 47]], ('en_core_web_trf', '208051', 8, 176): [[0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]], ('_en_core_sci_lg_nlp', '208051', 8, 176): [[101, 112, 109, 110, 142, 117, 103, 113, 115, 0, 114, 143, 1, 57, 118, 45, 22, 58], [119, 65, 79, 78, 131, 63, 77, 68, 122, 120, 73, 27, 23, 31, 133, 35, 64, 81], [101, 112, 109, 117, 142, 115, 118, 0, 1, 143, 110, 75, 103, 45, 57, 46, 114, 58], [64, 123, 121, 65, 119, 79, 131, 69, 138, 128, 97, 31, 23, 92, 87, 27, 78, 82], [76, 138, 128, 64, 131, 119, 79, 65, 123, 69, 121, 78, 35, 31, 32, 23, 36, 24], [101, 112, 142, 109, 117, 115, 0, 118, 110, 1, 143, 75, 103, 45, 57, 114, 22, 113], [101, 142, 112, 0, 109, 110, 103, 143, 1, 114, 111, 113, 117, 57, 115, 56, 44, 45], [101, 142, 112, 0, 109, 110, 1, 143, 103, 111, 114, 113, 56, 44, 57, 117, 115, 45]]}\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "FPpVmh_EkVy-",
        "outputId": "65acda3e-0ee2-4a59-f788-2e6a792c59e2"
      },
      "source": [
        "# Remove en_core_web_trf, since results indicate that there are no vectors\n",
        "scoring_method_list=[\n",
        "                     [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert, model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     [scoring_method_spacy, _en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"],]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1))"
      ],
      "execution_count": 106,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "processing 0 of 292\n",
            "processing 1 of 292\n",
            "processing 2 of 292\n",
            "processing 3 of 292\n",
            "processing 4 of 292\n",
            "processing 5 of 292\n",
            "processing 6 of 292\n",
            "processing 7 of 292\n",
            "processing 8 of 292\n",
            "processing 9 of 292\n",
            "processing 10 of 292\n",
            "processing 11 of 292\n",
            "processing 12 of 292\n",
            "processing 13 of 292\n",
            "processing 14 of 292\n",
            "processing 15 of 292\n",
            "processing 16 of 292\n",
            "processing 17 of 292\n",
            "processing 18 of 292\n",
            "processing 19 of 292\n",
            "processing 20 of 292\n",
            "processing 21 of 292\n",
            "processing 22 of 292\n",
            "processing 23 of 292\n",
            "processing 24 of 292\n",
            "processing 25 of 292\n",
            "processing 26 of 292\n",
            "processing 27 of 292\n",
            "processing 28 of 292\n",
            "processing 29 of 292\n",
            "processing 30 of 292\n",
            "processing 31 of 292\n",
            "processing 32 of 292\n",
            "processing 33 of 292\n",
            "processing 34 of 292\n",
            "processing 35 of 292\n",
            "processing 36 of 292\n",
            "processing 37 of 292\n",
            "processing 38 of 292\n",
            "processing 39 of 292\n",
            "processing 40 of 292\n",
            "processing 41 of 292\n",
            "processing 42 of 292\n",
            "processing 43 of 292\n",
            "processing 44 of 292\n",
            "processing 45 of 292\n",
            "processing 46 of 292\n",
            "processing 47 of 292\n",
            "processing 48 of 292\n",
            "processing 49 of 292\n",
            "processing 50 of 292\n",
            "processing 51 of 292\n",
            "processing 52 of 292\n",
            "processing 53 of 292\n",
            "processing 54 of 292\n",
            "processing 55 of 292\n",
            "processing 56 of 292\n",
            "processing 57 of 292\n",
            "processing 58 of 292\n",
            "processing 59 of 292\n",
            "processing 60 of 292\n",
            "processing 61 of 292\n",
            "processing 62 of 292\n",
            "processing 63 of 292\n",
            "processing 64 of 292\n",
            "processing 65 of 292\n",
            "processing 66 of 292\n",
            "processing 67 of 292\n",
            "processing 68 of 292\n",
            "processing 69 of 292\n",
            "processing 70 of 292\n",
            "processing 71 of 292\n",
            "processing 72 of 292\n",
            "processing 73 of 292\n",
            "processing 74 of 292\n",
            "processing 75 of 292\n",
            "processing 76 of 292\n",
            "processing 77 of 292\n",
            "processing 78 of 292\n",
            "processing 79 of 292\n",
            "processing 80 of 292\n",
            "processing 81 of 292\n",
            "processing 82 of 292\n",
            "processing 83 of 292\n",
            "processing 84 of 292\n",
            "processing 85 of 292\n",
            "processing 86 of 292\n",
            "processing 87 of 292\n",
            "processing 88 of 292\n",
            "processing 89 of 292\n",
            "processing 90 of 292\n",
            "processing 91 of 292\n",
            "processing 92 of 292\n",
            "processing 93 of 292\n",
            "processing 94 of 292\n",
            "processing 95 of 292\n",
            "processing 96 of 292\n",
            "processing 97 of 292\n",
            "processing 98 of 292\n",
            "processing 99 of 292\n",
            "processing 100 of 292\n",
            "processing 101 of 292\n",
            "processing 102 of 292\n",
            "processing 103 of 292\n",
            "processing 104 of 292\n",
            "processing 105 of 292\n",
            "processing 106 of 292\n",
            "processing 107 of 292\n",
            "processing 108 of 292\n",
            "processing 109 of 292\n",
            "processing 110 of 292\n",
            "processing 111 of 292\n",
            "processing 112 of 292\n",
            "processing 113 of 292\n",
            "processing 114 of 292\n",
            "processing 115 of 292\n",
            "processing 116 of 292\n",
            "processing 117 of 292\n",
            "processing 118 of 292\n",
            "processing 119 of 292\n",
            "processing 120 of 292\n",
            "processing 121 of 292\n",
            "processing 122 of 292\n",
            "processing 123 of 292\n",
            "processing 124 of 292\n",
            "processing 125 of 292\n",
            "processing 126 of 292\n",
            "processing 127 of 292\n",
            "processing 128 of 292\n",
            "processing 129 of 292\n",
            "processing 130 of 292\n",
            "processing 131 of 292\n",
            "processing 132 of 292\n",
            "processing 133 of 292\n",
            "processing 134 of 292\n",
            "processing 135 of 292\n",
            "processing 136 of 292\n",
            "processing 137 of 292\n",
            "processing 138 of 292\n",
            "processing 139 of 292\n",
            "processing 140 of 292\n",
            "processing 141 of 292\n",
            "processing 142 of 292\n",
            "processing 143 of 292\n",
            "processing 144 of 292\n",
            "processing 145 of 292\n",
            "processing 146 of 292\n",
            "processing 147 of 292\n",
            "processing 148 of 292\n",
            "processing 149 of 292\n",
            "processing 150 of 292\n",
            "processing 151 of 292\n",
            "processing 152 of 292\n",
            "processing 153 of 292\n",
            "processing 154 of 292\n",
            "processing 155 of 292\n",
            "processing 156 of 292\n",
            "processing 157 of 292\n",
            "processing 158 of 292\n",
            "processing 159 of 292\n",
            "processing 160 of 292\n",
            "processing 161 of 292\n",
            "processing 162 of 292\n",
            "processing 163 of 292\n",
            "processing 164 of 292\n",
            "processing 165 of 292\n",
            "processing 166 of 292\n",
            "processing 167 of 292\n",
            "processing 168 of 292\n",
            "processing 169 of 292\n",
            "processing 170 of 292\n",
            "processing 171 of 292\n",
            "processing 172 of 292\n",
            "processing 173 of 292\n",
            "processing 174 of 292\n",
            "processing 175 of 292\n",
            "processing 176 of 292\n",
            "processing 177 of 292\n",
            "processing 178 of 292\n",
            "processing 179 of 292\n",
            "processing 180 of 292\n",
            "processing 181 of 292\n",
            "processing 182 of 292\n",
            "processing 183 of 292\n",
            "processing 184 of 292\n",
            "processing 185 of 292\n",
            "processing 186 of 292\n",
            "processing 187 of 292\n",
            "processing 188 of 292\n",
            "processing 189 of 292\n",
            "processing 190 of 292\n",
            "processing 191 of 292\n",
            "processing 192 of 292\n",
            "processing 193 of 292\n",
            "processing 194 of 292\n",
            "processing 195 of 292\n",
            "processing 196 of 292\n",
            "processing 197 of 292\n",
            "processing 198 of 292\n",
            "processing 199 of 292\n",
            "processing 200 of 292\n",
            "processing 201 of 292\n",
            "processing 202 of 292\n",
            "processing 203 of 292\n",
            "processing 204 of 292\n",
            "processing 205 of 292\n",
            "processing 206 of 292\n",
            "processing 207 of 292\n",
            "processing 208 of 292\n",
            "processing 209 of 292\n",
            "processing 210 of 292\n",
            "processing 211 of 292\n",
            "processing 212 of 292\n",
            "processing 213 of 292\n",
            "processing 214 of 292\n",
            "processing 215 of 292\n",
            "processing 216 of 292\n",
            "processing 217 of 292\n",
            "processing 218 of 292\n",
            "processing 219 of 292\n",
            "processing 220 of 292\n",
            "processing 221 of 292\n",
            "processing 222 of 292\n",
            "processing 223 of 292\n",
            "processing 224 of 292\n",
            "processing 225 of 292\n",
            "processing 226 of 292\n",
            "processing 227 of 292\n",
            "processing 228 of 292\n",
            "processing 229 of 292\n",
            "processing 230 of 292\n",
            "processing 231 of 292\n",
            "processing 232 of 292\n",
            "processing 233 of 292\n",
            "processing 234 of 292\n",
            "processing 235 of 292\n",
            "processing 236 of 292\n",
            "processing 237 of 292\n",
            "processing 238 of 292\n",
            "processing 239 of 292\n",
            "processing 240 of 292\n",
            "processing 241 of 292\n",
            "processing 242 of 292\n",
            "processing 243 of 292\n",
            "processing 244 of 292\n",
            "processing 245 of 292\n",
            "processing 246 of 292\n",
            "processing 247 of 292\n",
            "processing 248 of 292\n",
            "processing 249 of 292\n",
            "processing 250 of 292\n",
            "processing 251 of 292\n",
            "processing 252 of 292\n",
            "processing 253 of 292\n",
            "processing 254 of 292\n",
            "processing 255 of 292\n",
            "processing 256 of 292\n",
            "processing 257 of 292\n",
            "processing 258 of 292\n",
            "processing 259 of 292\n",
            "processing 260 of 292\n",
            "processing 261 of 292\n",
            "processing 262 of 292\n",
            "processing 263 of 292\n",
            "processing 264 of 292\n",
            "processing 265 of 292\n",
            "processing 266 of 292\n",
            "processing 267 of 292\n",
            "processing 268 of 292\n",
            "processing 269 of 292\n",
            "processing 270 of 292\n",
            "processing 271 of 292\n",
            "processing 272 of 292\n",
            "processing 273 of 292\n",
            "processing 274 of 292\n",
            "processing 275 of 292\n",
            "processing 276 of 292\n",
            "processing 277 of 292\n",
            "processing 278 of 292\n",
            "processing 279 of 292\n",
            "processing 280 of 292\n",
            "processing 281 of 292\n",
            "processing 282 of 292\n",
            "processing 283 of 292\n",
            "processing 284 of 292\n",
            "processing 285 of 292\n",
            "processing 286 of 292\n",
            "processing 287 of 292\n",
            "processing 288 of 292\n",
            "processing 289 of 292\n",
            "processing 290 of 292\n",
            "processing 291 of 292\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 425
        },
        "id": "r7fmhyKbpFFx",
        "outputId": "b1a4e85e-1e92-438a-bad1-f596effdc312"
      },
      "source": [
        "# print(multi_return_match_result[0])\n",
        "# import json\n",
        "# json=json.dumps(multi_return_match_result)\n",
        "# f=open(\"multi_match_result.json\", \"w\")\n",
        "# f.write(json)\n",
        "# f.close()"
      ],
      "execution_count": 107,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "{('model_mpnet_base_v2', '202895-21976', 52, 121): [[58, 31, 71, 63, 59, 56, 32, 50, 52, 54, 55, 15, 67], [58, 31, 63, 53, 56, 71, 55, 32, 51, 59, 50, 54, 60], [63, 58, 53, 51, 0, 31, 56, 54, 15, 33, 60, 71, 52], [58, 53, 51, 31, 56, 54, 71, 52, 59, 55, 32, 63, 50], [84, 2, 119, 75, 105, 114, 104, 117, 116, 3, 115, 15, 46], [84, 2, 114, 104, 111, 119, 102, 116, 107, 110, 117, 81, 115], [58, 31, 71, 63, 53, 32, 67, 15, 59, 51, 60, 0, 56], [30, 28, 25, 95, 58, 31, 27, 0, 63, 53, 26, 91, 108], [74, 72, 63, 20, 104, 102, 33, 15, 92, 60, 58, 51, 57], [49, 104, 5, 102, 111, 92, 74, 84, 116, 43, 72, 80, 34], [117, 104, 116, 49, 119, 111, 74, 102, 39, 92, 15, 114, 33], [104, 102, 15, 33, 119, 4, 74, 114, 31, 60, 63, 0, 58], [104, 102, 107, 58, 114, 15, 74, 110, 33, 31, 119, 113, 120], [20, 57, 60, 19, 92, 91, 39, 75, 105, 58, 79, 109, 50], [74, 72, 104, 102, 15, 33, 0, 107, 120, 90, 63, 103, 20], [104, 102, 58, 15, 110, 112, 74, 72, 33, 31, 107, 63, 87], [58, 31, 91, 92, 63, 51, 60, 90, 87, 53, 15, 0, 108], [72, 74, 102, 104, 90, 20, 63, 103, 112, 15, 87, 4, 33], [104, 102, 74, 81, 87, 72, 120, 80, 20, 4, 79, 109, 15], [104, 76, 106, 81, 102, 4, 5, 120, 49, 58, 74, 80, 0], [104, 120, 102, 87, 74, 107, 1, 72, 79, 109, 80, 0, 108], [30, 95, 28, 25, 27, 58, 75, 105, 63, 53, 0, 31, 26], [95, 30, 0, 60, 63, 31, 58, 91, 15, 33, 28, 57, 75], [91, 63, 58, 31, 0, 60, 33, 95, 15, 57, 35, 108, 19], [104, 102, 107, 58, 114, 15, 74, 110, 33, 31, 119, 113, 120], [104, 102, 58, 15, 110, 112, 74, 72, 33, 31, 107, 63, 87], [5, 81, 76, 106, 104, 102, 120, 49, 77, 6, 40, 4, 43], [58, 31, 63, 71, 0, 32, 80, 15, 59, 50, 56, 33, 60], [58, 63, 95, 0, 31, 30, 60, 80, 15, 17, 33, 91, 51], [104, 74, 102, 33, 15, 107, 72, 0, 90, 120, 103, 1, 4], [58, 31, 63, 71, 53, 51, 55, 60, 15, 32, 56, 92, 33], [102, 104, 119, 92, 117, 114, 120, 75, 105, 74, 93, 107, 116], [74, 72, 43, 20, 21, 4, 19, 104, 116, 102, 55, 107, 99], [20, 57, 60, 92, 91, 19, 75, 105, 39, 79, 109, 63, 90], [74, 72, 90, 63, 102, 104, 33, 15, 0, 117, 103, 114, 112], [74, 72, 104, 102, 15, 33, 0, 107, 120, 90, 63, 103, 20], [49, 92, 58, 55, 31, 50, 63, 111, 51, 81, 60, 9, 5], [49, 72, 74, 5, 92, 11, 102, 6, 104, 9, 63, 40, 7], [49, 92, 55, 58, 31, 20, 63, 39, 51, 75, 105, 53, 50], [72, 74, 117, 102, 92, 49, 20, 104, 39, 116, 33, 15, 119], [58, 31, 92, 91, 108, 78, 63, 55, 107, 56, 53, 60, 51], [72, 74, 107, 102, 104, 103, 120, 114, 112, 90, 33, 92, 4], [58, 31, 91, 92, 63, 51, 60, 90, 87, 53, 15, 0, 108], [104, 74, 102, 33, 15, 107, 72, 0, 120, 90, 103, 1, 4], [102, 104, 74, 72, 120, 4, 20, 33, 15, 67, 21, 0, 65], [74, 72, 90, 102, 104, 33, 63, 112, 117, 0, 15, 114, 92], [49, 72, 74, 5, 92, 6, 102, 11, 104, 43, 7, 9, 111], [74, 72, 117, 92, 102, 104, 49, 116, 20, 33, 119, 39, 15], [72, 74, 107, 102, 104, 103, 120, 114, 90, 112, 92, 33, 4], [72, 74, 102, 104, 90, 87, 112, 20, 103, 4, 15, 33, 0], [4, 67, 104, 0, 11, 20, 31, 102, 15, 58, 120, 33, 21], [4, 67, 11, 20, 0, 104, 21, 102, 15, 31, 5, 1, 33]], ('model_roberta_base_v2', '202895-21976', 52, 121): [[58, 31, 55, 71, 49, 56, 63, 59, 51, 60, 32, 53, 50], [58, 31, 55, 51, 49, 53, 56, 52, 32, 54, 71, 60, 63], [91, 58, 51, 31, 63, 55, 95, 49, 53, 60, 52, 33, 71], [58, 31, 51, 53, 55, 49, 54, 60, 52, 56, 32, 63, 59], [37, 44, 43, 73, 45, 84, 62, 75, 105, 56, 38, 115, 3], [44, 45, 73, 37, 77, 81, 84, 62, 108, 78, 98, 35, 5], [31, 58, 49, 55, 51, 32, 71, 53, 63, 52, 60, 59, 54], [30, 17, 18, 95, 28, 91, 31, 63, 60, 59, 58, 51, 53], [72, 74, 102, 104, 20, 87, 55, 21, 58, 4, 33, 63, 67], [55, 74, 56, 72, 49, 54, 58, 59, 52, 104, 102, 38, 27], [55, 56, 72, 74, 102, 58, 104, 53, 38, 49, 51, 59, 84], [58, 53, 56, 55, 60, 87, 31, 59, 49, 4, 54, 72, 37], [56, 55, 72, 84, 58, 81, 53, 77, 74, 62, 87, 99, 51], [91, 72, 74, 92, 58, 99, 4, 33, 102, 104, 20, 87, 49], [74, 72, 104, 102, 33, 15, 20, 87, 0, 21, 4, 120, 117], [72, 58, 74, 55, 87, 31, 59, 56, 32, 49, 37, 51, 84], [58, 91, 31, 51, 53, 55, 49, 87, 71, 59, 92, 56, 84], [72, 74, 87, 58, 55, 104, 102, 31, 119, 115, 59, 32, 117], [102, 120, 87, 104, 84, 72, 4, 74, 115, 99, 81, 116, 119], [62, 86, 53, 58, 76, 106, 81, 56, 43, 99, 54, 84, 83], [87, 120, 74, 104, 102, 72, 4, 67, 11, 90, 115, 116, 117], [30, 28, 95, 91, 17, 63, 18, 31, 60, 58, 53, 51, 19], [91, 28, 30, 31, 51, 17, 63, 18, 53, 55, 49, 60, 58], [91, 51, 31, 55, 28, 58, 49, 53, 19, 52, 63, 17, 32], [56, 55, 72, 84, 58, 81, 53, 77, 74, 62, 87, 99, 51], [72, 58, 74, 55, 87, 31, 59, 56, 32, 49, 37, 51, 84], [62, 86, 76, 106, 108, 43, 99, 83, 78, 81, 84, 66, 87], [58, 31, 55, 71, 49, 63, 56, 60, 51, 59, 53, 50, 52], [58, 31, 52, 51, 59, 95, 63, 55, 30, 17, 56, 60, 49], [74, 15, 104, 33, 20, 102, 0, 72, 120, 4, 21, 87, 1], [58, 31, 55, 49, 53, 51, 63, 32, 71, 56, 60, 59, 52], [115, 114, 119, 117, 116, 84, 104, 102, 118, 112, 111, 74, 110], [72, 74, 38, 102, 104, 107, 116, 119, 117, 21, 115, 15, 118], [91, 92, 72, 74, 99, 4, 33, 58, 87, 102, 104, 20, 89], [72, 74, 87, 102, 63, 104, 112, 58, 55, 20, 71, 33, 21], [74, 72, 104, 102, 33, 15, 20, 87, 0, 21, 4, 120, 117], [91, 55, 58, 49, 53, 98, 31, 102, 4, 64, 51, 84, 8], [72, 74, 55, 104, 102, 49, 56, 52, 54, 32, 58, 38, 28], [55, 53, 58, 92, 91, 51, 49, 102, 4, 56, 84, 31, 67], [72, 74, 55, 102, 104, 56, 38, 53, 58, 120, 51, 116, 115], [91, 81, 58, 62, 53, 51, 99, 84, 55, 92, 108, 4, 49], [72, 74, 102, 77, 62, 104, 55, 120, 51, 107, 87, 99, 58], [58, 91, 31, 51, 53, 55, 49, 87, 71, 59, 92, 56, 84], [74, 15, 104, 33, 20, 102, 0, 72, 120, 4, 21, 87, 1], [72, 74, 102, 120, 104, 4, 87, 33, 11, 15, 67, 20, 21], [72, 74, 87, 63, 104, 102, 112, 71, 58, 55, 20, 33, 60], [74, 72, 55, 104, 49, 102, 56, 58, 52, 54, 28, 32, 31], [72, 55, 74, 104, 102, 56, 53, 38, 58, 51, 116, 63, 49], [72, 74, 102, 62, 104, 77, 55, 120, 51, 99, 58, 87, 107], [72, 74, 87, 58, 104, 55, 31, 102, 59, 119, 115, 117, 32], [71, 55, 49, 28, 56, 19, 82, 16, 96, 38, 8, 17, 108], [71, 38, 55, 16, 56, 19, 17, 28, 96, 49, 58, 59, 37]], ('_en_core_sci_lg_nlp', '202895-21976', 52, 121): [[19, 28, 60, 31, 51, 58, 53, 55, 49, 50, 52, 32, 71], [54, 52, 56, 63, 32, 50, 53, 51, 55, 71, 49, 28, 31], [63, 56, 52, 54, 32, 50, 71, 59, 94, 60, 51, 53, 55], [52, 56, 54, 32, 50, 71, 59, 63, 60, 51, 53, 57, 55], [49, 58, 31, 55, 53, 51, 19, 92, 28, 111, 50, 90, 59], [49, 58, 55, 31, 53, 51, 92, 19, 28, 111, 50, 90, 114], [54, 52, 56, 32, 50, 63, 53, 51, 55, 71, 19, 28, 49], [59, 71, 51, 58, 53, 31, 52, 55, 56, 54, 28, 32, 63], [49, 58, 31, 55, 19, 53, 51, 28, 63, 111, 50, 60, 114], [49, 55, 31, 51, 58, 53, 19, 28, 50, 54, 56, 32, 52], [49, 31, 58, 55, 51, 53, 19, 28, 50, 71, 63, 59, 32], [49, 58, 31, 55, 53, 51, 19, 28, 50, 63, 71, 59, 32], [49, 58, 31, 55, 53, 51, 19, 28, 50, 63, 71, 59, 32], [91, 111, 92, 104, 112, 113, 114, 110, 90, 116, 117, 76, 106], [90, 74, 104, 111, 72, 102, 114, 112, 113, 110, 107, 89, 77], [49, 58, 31, 55, 53, 51, 19, 28, 63, 50, 71, 59, 92], [49, 58, 55, 31, 53, 91, 51, 92, 19, 28, 63, 111, 59], [49, 31, 58, 55, 51, 53, 19, 28, 50, 71, 63, 59, 32], [107, 104, 74, 111, 77, 120, 90, 114, 112, 76, 106, 113, 102], [111, 120, 112, 104, 114, 113, 116, 90, 92, 110, 88, 107, 74], [107, 104, 74, 77, 120, 76, 106, 111, 102, 79, 109, 114, 112], [51, 28, 53, 31, 55, 58, 19, 63, 52, 49, 56, 54, 32], [51, 52, 53, 56, 55, 54, 31, 28, 32, 58, 19, 49, 71], [52, 56, 54, 51, 53, 32, 55, 31, 28, 58, 71, 49, 19], [49, 58, 31, 55, 53, 51, 19, 28, 50, 63, 71, 59, 32], [49, 58, 31, 55, 53, 51, 19, 28, 63, 50, 71, 59, 92], [104, 120, 111, 107, 112, 114, 113, 92, 116, 74, 110, 90, 88], [19, 28, 60, 31, 58, 51, 53, 49, 55, 50, 71, 32, 52], [28, 58, 59, 31, 19, 71, 51, 53, 63, 55, 49, 32, 52], [90, 74, 104, 72, 102, 111, 114, 112, 107, 113, 110, 77, 89], [60, 52, 54, 56, 32, 19, 28, 50, 63, 71, 51, 53, 55], [92, 111, 49, 90, 114, 113, 112, 91, 58, 55, 31, 110, 53], [111, 112, 114, 113, 72, 74, 110, 104, 102, 116, 92, 117, 49], [91, 92, 111, 112, 104, 113, 114, 110, 90, 116, 117, 107, 74], [49, 58, 31, 55, 51, 53, 19, 28, 50, 63, 71, 60, 59], [90, 74, 104, 111, 72, 102, 114, 112, 113, 110, 107, 89, 77], [49, 55, 53, 31, 51, 91, 58, 92, 19, 50, 28, 56, 63], [49, 55, 31, 51, 53, 58, 19, 28, 50, 54, 56, 32, 52], [49, 55, 58, 31, 53, 51, 91, 92, 19, 50, 28, 63, 59], [49, 31, 58, 55, 51, 53, 19, 28, 50, 71, 63, 59, 92], [49, 55, 58, 31, 53, 51, 91, 92, 19, 28, 63, 50, 59], [49, 31, 58, 55, 51, 53, 19, 28, 50, 63, 71, 59, 32], [49, 58, 55, 31, 53, 91, 51, 92, 19, 28, 63, 111, 59], [90, 74, 104, 72, 102, 111, 114, 112, 107, 113, 110, 77, 89], [31, 49, 58, 55, 51, 53, 19, 28, 63, 60, 71, 50, 32], [49, 58, 31, 55, 51, 53, 19, 28, 63, 50, 71, 60, 59], [49, 55, 31, 51, 53, 58, 19, 28, 50, 54, 56, 52, 32], [49, 58, 31, 55, 51, 53, 19, 28, 50, 71, 63, 59, 32], [49, 31, 58, 55, 51, 53, 19, 28, 50, 63, 71, 59, 32], [49, 31, 58, 55, 51, 53, 19, 28, 50, 63, 71, 59, 32], [31, 19, 58, 28, 51, 53, 49, 55, 60, 63, 71, 32, 59], [19, 28, 31, 58, 51, 53, 55, 49, 60, 63, 71, 57, 32]]}\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "error",
          "ename": "TypeError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-107-4b80a9ac733a>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmulti_return_match_result\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[0;32mimport\u001b[0m \u001b[0mjson\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 3\u001b[0;31m \u001b[0mjson\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mjson\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdumps\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmulti_return_match_result\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      4\u001b[0m \u001b[0mf\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"multi_match_result.json\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"w\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0mf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwrite\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mjson\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.7/json/__init__.py\u001b[0m in \u001b[0;36mdumps\u001b[0;34m(obj, skipkeys, ensure_ascii, check_circular, allow_nan, cls, indent, separators, default, sort_keys, **kw)\u001b[0m\n\u001b[1;32m    229\u001b[0m         \u001b[0mcls\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mindent\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mseparators\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m \u001b[0;32mand\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    230\u001b[0m         default is None and not sort_keys and not kw):\n\u001b[0;32m--> 231\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0m_default_encoder\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mobj\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    232\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mcls\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    233\u001b[0m         \u001b[0mcls\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mJSONEncoder\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.7/json/encoder.py\u001b[0m in \u001b[0;36mencode\u001b[0;34m(self, o)\u001b[0m\n\u001b[1;32m    197\u001b[0m         \u001b[0;31m# exceptions aren't as detailed.  The list call should be roughly\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    198\u001b[0m         \u001b[0;31m# equivalent to the PySequence_Fast that ''.join() would do.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 199\u001b[0;31m         \u001b[0mchunks\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0miterencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mo\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0m_one_shot\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    200\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mchunks\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mlist\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtuple\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    201\u001b[0m             \u001b[0mchunks\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlist\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mchunks\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.7/json/encoder.py\u001b[0m in \u001b[0;36miterencode\u001b[0;34m(self, o, _one_shot)\u001b[0m\n\u001b[1;32m    255\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mkey_separator\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mitem_separator\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msort_keys\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    256\u001b[0m                 self.skipkeys, _one_shot)\n\u001b[0;32m--> 257\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0m_iterencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mo\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    258\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    259\u001b[0m def _make_iterencode(markers, _default, _encoder, _indent, _floatstr,\n",
            "\u001b[0;31mTypeError\u001b[0m: keys must be str, int, float, bool or None, not tuple"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "Q7Gn4JM7yYkW",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d4a81011-a56d-4f13-80b1-7be73a962780"
      },
      "source": [
        "def mean(lst):\n",
        "  return sum(lst)/len(lst)\n",
        "\n",
        "def return_mean_percent_same_for_each_nda(multi_return_match_result):\n",
        "  # calculate percentage that match\n",
        "  # percent_same_for_each_nda is a list of percentages of claims that are the same for each addtion for each NDA\n",
        "  percent_same_for_each_nda=[]\n",
        "  for NDA in multi_return_match_result:\n",
        "    # matches = [[[claim_index1,claim_index2,],],] wherein the outermost list represents list for each model, the second outermost list represented the additions\n",
        "    matches=[]\n",
        "    model_names=[]\n",
        "    # breakup dict into lists; the format of the dict is {(method_name, NDA, len(additions), len(claims)):matches, ...}\n",
        "    for key, value in NDA.items():\n",
        "      model_names.append(key[0])\n",
        "      matches.append(value)\n",
        "    if not matches or not matches[0] or not matches[0][0]:\n",
        "      continue\n",
        "\n",
        "    models_len=len(matches)\n",
        "    additions_len=len(matches[0])\n",
        "    claims_len=len(matches[0][0])\n",
        "\n",
        "    # additions_percent_same is a list of the percentage of additions that have same claim_indexes across multiple models for each addition in an NDA\n",
        "    additions_percent_same=[]\n",
        "\n",
        "    for a in range(additions_len):\n",
        "      # addition_matches=[[claim_index1,claim_index2,],] wherein each row represents a different model\n",
        "      addition_matches=[]\n",
        "      for m in range(models_len):\n",
        "        addition_matches.append(matches[m][a])\n",
        "      # count number of claim_index that is the same across multiple models for same addition\n",
        "      same_claims=addition_matches[0]\n",
        "      same_claims_orig_len=len(same_claims)\n",
        "      assert same_claims_orig_len==claims_len\n",
        "      for i in range(1,len(addition_matches)):\n",
        "        same_claims=list(set(same_claims).intersection(addition_matches[i]))\n",
        "      percent_same=len(same_claims)/same_claims_orig_len\n",
        "      additions_percent_same.append(percent_same)\n",
        "    \n",
        "    percent_same_for_each_nda.append(mean(additions_percent_same))\n",
        "  return mean(percent_same_for_each_nda)\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))\n",
        "  "
      ],
      "execution_count": 108,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  0.3022827958802241\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "B-qwMIRwiB30"
      },
      "source": [
        "The above indicates that if three models are used, the top 10% of the results are shared by 30% of the models.  The following indicates if 2 models are using the results are shared by 55% of the two models."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Y-7T_DWEz3kU",
        "outputId": "88dd8a73-d33b-4073-ba78-b82ee61a773a"
      },
      "source": [
        "scoring_method_list=[\n",
        "                     [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_spacy,_en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"],\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1))\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))"
      ],
      "execution_count": 109,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  0.4189151577329994\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mks4GYowNKG5",
        "outputId": "5336dbfe-dd3c-4edd-f8d0-2420d14a74e9"
      },
      "source": [
        "scoring_method_list=[\n",
        "                     [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert,model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1))\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))"
      ],
      "execution_count": 110,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  0.5502248546898962\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "MWcqslfqhrEM"
      },
      "source": [
        "If a single model is use, the following should report 1, since all matches are the same to itself."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xYfPng0qf1Zr",
        "outputId": "782ad515-22ef-41bb-86ad-13d93b6b8f6f"
      },
      "source": [
        "scoring_method_list=[\n",
        "                     [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1))\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))"
      ],
      "execution_count": 111,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  1.0\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Uv9TahFAip5L"
      },
      "source": [
        "If the cutoff percentage increases, then the number of matching claims should increase."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "m9rJ8aTqgoZ7",
        "outputId": "38046ce6-a152-419b-b1c7-24c30bf91348"
      },
      "source": [
        "scoring_method_list=[\n",
        "                      [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert,model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     [scoring_method_spacy,_en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"]\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.2))\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))"
      ],
      "execution_count": 112,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  0.38887973947123505\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ukjN1Ob5gl4M",
        "outputId": "5ddd3b40-700b-4c0c-d448-d016400f7fc0"
      },
      "source": [
        "scoring_method_list=[\n",
        "                      [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert,model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     [scoring_method_spacy,_en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"]\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.3))\n",
        "\n",
        "print(\"Mean percent_same_for_each_nda: \", return_mean_percent_same_for_each_nda(multi_return_match_result))"
      ],
      "execution_count": 113,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Mean percent_same_for_each_nda:  0.45128598488193755\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "lEjT1H9fwgcD"
      },
      "source": [
        "scoring_method_list=[\n",
        "                      [scoring_method_bert, model_mpnet_base_v2, \"model_mpnet_base_v2\"],\n",
        "                     [scoring_method_bert,model_roberta_base_v2, \"model_roberta_base_v2\"],\n",
        "                     [scoring_method_spacy,_en_core_sci_lg_nlp, \"_en_core_sci_lg_nlp\"]\n",
        "                     ]\n",
        "\n",
        "multi_return_match_result=[]\n",
        "for i in range(len(random_NDA_list)):\n",
        "  # print(f\"processing {str(i)} of {str(len(random_NDA_list))}\")\n",
        "  NDA=random_NDA_list[i]\n",
        "  multi_return_match_result.append(return_match(NDA, \"additions_with_context\", \"patents\", scoring_method_list, cutoff_percentage=.1))"
      ],
      "execution_count": 152,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "NTHOK619jKAC"
      },
      "source": [
        "def print_top_percentage_multi(multi_return_match_result, NDA_, additions_folder_name, patent_folder_name):\n",
        "  \"\"\"\n",
        "  Prints the same matches from an NDA\n",
        "  Parameters:\n",
        "    multi_return_match_result=[{ (\"method_name\", NDA, len(additions), len(claims)): [[additions_num, claim_num],], },] for a list of NDA\n",
        "  \"\"\"\n",
        "  # calculate percentage that match\n",
        "  # percent_same_for_each_nda is a list of percentages of claims that are the same for each addtion for each NDA\n",
        "  for NDA_set in multi_return_match_result:\n",
        "    # print(str(NDA)[:50])\n",
        "    key_=list(NDA_set.keys())[0]\n",
        "    value_ = NDA_set.values()\n",
        "    if key_[1]!=NDA_:\n",
        "      continue\n",
        "    claims = get_patent_claims(NDA, patent_folder_name)\n",
        "    additions = get_additions(NDA, additions_folder_name)\n",
        "\n",
        "    # matches = [[[claim_index1,claim_index2,],],] wherein the outermost list represents list for each model, the second outermost list represented the additions\n",
        "    matches=[]\n",
        "\n",
        "    # breakup dict into lists; the format of the dict is {(method_name, NDA, len(additions), len(claims)):matches, ...}\n",
        "    for key, value in NDA_set.items():\n",
        "      matches.append(value)\n",
        "    if not matches or not matches[0] or not matches[0][0]:\n",
        "      continue\n",
        "\n",
        "    models_len=len(matches)\n",
        "    additions_len=len(matches[0])\n",
        "    claims_len=len(matches[0][0])\n",
        "\n",
        "    print(f\"==NDA: {NDA_}\")\n",
        "    patent_dir=db2files+str(NDA)+'/'+patent_folder_name+'/'\n",
        "    if os.path.exists(patent_dir):\n",
        "      patent_files=[patent_dir+f for f in os.listdir(patent_dir)]\n",
        "      patent_files=[f.split('/')[-1] for f in patent_files]\n",
        "    print(f\"==patents: {patent_files}\")\n",
        "\n",
        "    for a in range(additions_len):\n",
        "\n",
        "      # addition_matches=[[claim_index1,claim_index2,],] wherein each row represents a different model\n",
        "      addition_matches=[]\n",
        "      for m in range(models_len):\n",
        "        addition_matches.append(matches[m][a])\n",
        "      # count number of claim_index that is the same across multiple models for same addition\n",
        "      same_claims=addition_matches[0]\n",
        "      same_claims_orig_len=len(same_claims)\n",
        "      assert same_claims_orig_len==claims_len\n",
        "      for i in range(1,len(addition_matches)):\n",
        "        same_claims=list(set(same_claims).intersection(addition_matches[i]))\n",
        "\n",
        "      if same_claims:\n",
        "        print(f\"==addition: {additions[a]}\")\n",
        "        print(f'==same_claims_list: {same_claims}')\n",
        "        \n",
        "        for c in same_claims:\n",
        "          print(f\"********claim: \\n{claims[c]}\")\n",
        "  \n",
        "    \n",
        "    break\n",
        "    \n",
        "  "
      ],
      "execution_count": 167,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sTMwC8nAZ6gS",
        "outputId": "44ef0566-630d-4001-eb19-262f84178f69"
      },
      "source": [
        "# Change i to see all addition to claim matching \n",
        "i=1\n",
        "NDA=random_NDA_list[0]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 168,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 202895-21976\n",
            "==patents: ['8597876', '9889115', '7470506', '7700645', '6987102', '8518987']\n",
            "==addition: PREZISTA®, co-administered with ritonavir (PREZISTA/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection.\n",
            "\n",
            "==same_claims_list: [32, 71, 50, 55, 58, 31]\n",
            "********claim: \n",
            "33. The method of claim 32, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "51. The method of claim 50, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), and with other antiretroviral agents, is indicated for the treatment of HIV infection in pediatric patients 6 years of age and older  [see Use in Specific Populations (8.4)\n",
            "].\n",
            "\n",
            "==same_claims_list: [32, 71, 51, 53, 54, 55, 56, 31, 63]\n",
            "********claim: \n",
            "33. The method of claim 32, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "55. The method of claim 54, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "57. The method of claim 56, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with PREZISTA/ritonavir:\n",
            "Treatment history and, when available, genotypic or phenotypic testing should guide the use of PREZISTA/ritonavir [see Clinical Pharmacology (12.4)\n",
            "].\n",
            "\n",
            "==same_claims_list: [71, 51, 52, 53, 60, 63]\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "53. The method of claim 52, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "4. A method of preventing the development of protease inhibitor resistance in an HIV-infected mammal, the method comprising administering to the HIV-infected mammal a protease inhibitor resistance-inhibiting effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein the protease inhibitor resistance-inhibiting effective amount is an amount sufficient to produce an in vivo protease inhibitor concentration or level in which a mutant virus that is capable of evolving from the HIV virus infecting the mammal has lower fitness, relative to the HIV virus infecting the mammal, in the presence of the compound, and\n",
            "wherein the method comprises further administration of at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: The use of other active agents with PREZISTA/ritonavir is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14.3)\n",
            "].\n",
            "\n",
            "==same_claims_list: [32, 51, 52, 53, 54, 55, 56, 59, 63]\n",
            "********claim: \n",
            "33. The method of claim 32, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "53. The method of claim 52, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "55. The method of claim 54, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "57. The method of claim 56, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older [see Use in Specific Populations (8.4)\n",
            "].\n",
            "\n",
            "==same_claims_list: [32, 71, 51, 53, 63]\n",
            "********claim: \n",
            "33. The method of claim 32, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: This indication is based on 24-week analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 open-label Phase 2 trials in antiretroviral treatment-experienced pediatric patients (one trial in patients 6 to less than 18 years of age and one trial in patients 3 to less than 6 years of age).\n",
            "\n",
            "==same_claims_list: [31, 53, 58, 28, 63]\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 24, wherein the mutant retrovirus is resistant to at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 100 mg/mL oral suspension is supplied as a white to off-white opaque suspension for oral use, containing darunavir ethanolate equivalent to 100 mg of darunavir per mL of suspension.\n",
            "\n",
            "==same_claims_list: [58, 63]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 75 mg tablets are supplied as white, caplet-shaped, film-coated tablets containing darunavir ethanolate equivalent to 75 mg of darunavir per tablet. Each tablet is debossed with \"75\" on one side and \"TMC\" on the other side.\n",
            "\n",
            "==same_claims_list: [49]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 150 mg tablets are supplied as white, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 150 mg of darunavir per tablet. Each tablet is debossed with \"150\" on one side and \"TMC\" on the other side.\n",
            "\n",
            "==same_claims_list: [49]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 400 mg tablets are supplied as light orange, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 400 mg of darunavir per tablet. Each tablet is debossed with \"400MG\" on one side and \"TMC\" on the other side.\n",
            "\n",
            "==same_claims_list: [58, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 600 mg tablets are supplied as orange, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 600 mg of darunavir per tablet. Each tablet is debossed with \"600MG\" on one side and \"TMC\" on the other side.\n",
            "\n",
            "==same_claims_list: [58]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA 100 mg/mL oral suspension is available as a white to off-white opaque suspension for oral administration.\n",
            "\n",
            "\n",
            "==same_claims_list: [91, 92]\n",
            "********claim: \n",
            "12. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "==addition: Each mL of the oral suspension contains darunavir ethanolate equivalent to 100 mg darunavir. In addition, each mL contains the inactive ingredients hydroxypropyl cellulose, microcrystalline cellulose, sodium carboxymethylcellulose, methylparaben sodium, citric acid monohydrate, sucralose, masking flavor, strawberry cream flavor, hydrochloric acid (for pH adjustment) and purified water.\n",
            "\n",
            "\n",
            "==same_claims_list: [104, 74, 72, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 800 mg tablets are supplied as dark red, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 800 mg of darunavir per tablet. Each tablet is debossed with \"800\" on one side and \"T\" on the other side.\n",
            "\n",
            "==same_claims_list: [58, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition:  PREZISTA 800 mg tablets are available as dark red, oval-shaped, film-coated tablets for oral administration.\n",
            "\n",
            "==same_claims_list: [51, 53, 58, 91, 92, 31]\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: The 800 mg tablet also contains hypromellose. The 75 and 150 mg tablet film coating, OPADRY® White, contains polyethylene glycol 3350, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.\n",
            "\n",
            "==same_claims_list: [104, 74, 120, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "19. The composition of claim 3 further comprising amorphous (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition:  The 800 mg tablet film coating, OPADRY® Dark Red, contains iron oxide red, polyethylene glycol 3350, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.\n",
            "\n",
            "==same_claims_list: [104, 74, 120, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "19. The composition of claim 3 further comprising amorphous (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition: The indication for treatment-experienced pediatric patients 3 to less than 18 years of age is based on 24-week analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two open-label Phase 2 trials in antiretroviral treatment-experienced pediatric subjects.\n",
            "\n",
            "==same_claims_list: [31, 53, 58, 28, 63]\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 24, wherein the mutant retrovirus is resistant to at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: The indication for treatment-experienced pediatric patients 3 to less than 18 years of age is based on 24-week analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two open-label Phase 2 trials in antiretroviral treatment-experienced pediatric subjects. The indication for treatment-naïve pediatric patients or antiretroviral treatment-experienced patients with no darunavir resistance associated substitutions is based on one open-label Phase 2 trial of 48 weeks duration in antiretroviral treatment-naïve subjects 12 to less than 18 years of age and pharmacokinetic modeling and simulation for patients 3 to less than 12 years of age.\n",
            "\n",
            "==same_claims_list: [58, 28, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 24, wherein the mutant retrovirus is resistant to at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: The indication for treatment-naïve pediatric patients or antiretroviral treatment-experienced patients with no darunavir resistance associated substitutions is based on one open-label Phase 2 trial of 48 weeks duration in antiretroviral treatment-naïve subjects 12 to less than 18 years of age and pharmacokinetic modeling and simulation for patients 3 to less than 12 years of age.\n",
            "\n",
            "==same_claims_list: [58, 19, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "20. The method of claim 16, wherein the mutant retrovirus is resistant to at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 600 mg tablets are supplied as orange, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 600 mg of darunavir per tablet. Each tablet is debossed with \"600MG\" on one side and \"TMC\" on the other side.\n",
            "\n",
            "==same_claims_list: [58]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA (darunavir) 800 mg tablets are supplied as dark red, oval-shaped, film-coated tablets containing darunavir ethanolate equivalent to 800 mg of darunavir per tablet. Each tablet is debossed with \"800\" on one side and \"T\" on the other side.\n",
            "\n",
            "==same_claims_list: [58, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: PREZISTA®, co-administered with cobicistat (PREZISTA/cobicistat) or ritonavir (PREZISTA/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection.\n",
            "\n",
            "==same_claims_list: [71, 50, 58, 60, 31]\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "51. The method of claim 50, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "4. A method of preventing the development of protease inhibitor resistance in an HIV-infected mammal, the method comprising administering to the HIV-infected mammal a protease inhibitor resistance-inhibiting effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein the protease inhibitor resistance-inhibiting effective amount is an amount sufficient to produce an in vivo protease inhibitor concentration or level in which a mutant virus that is capable of evolving from the HIV virus infecting the mammal has lower fitness, relative to the HIV virus infecting the mammal, in the presence of the compound, and\n",
            "wherein the method comprises further administration of at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 controlled darunavir/ritonavir Phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients and 2 controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.\n",
            "\n",
            "==same_claims_list: [58, 51, 63, 31]\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: In addition, each mL contains the inactive ingredients citric acid monohydrate, hydrochloric acid (for pH adjustment), hydroxypropyl cellulose, masking flavor, methylparaben sodium, microcrystalline cellulose, purified water, sodium carboxymethylcellulose, strawberry cream flavor, and sucralose.\n",
            "\n",
            "==same_claims_list: [104, 74, 72, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition: PREZISTA®, co-administered with ritonavir (PREZISTA/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations (8.4) and Clinical Studies (14)].\n",
            "\n",
            "==same_claims_list: [32, 71, 51, 53, 55, 56, 60, 63]\n",
            "********claim: \n",
            "33. The method of claim 32, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the at least one antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "57. The method of claim 56, wherein the at least one other antiviral agent is ritonavir.\n",
            "\n",
            "********claim: \n",
            "4. A method of preventing the development of protease inhibitor resistance in an HIV-infected mammal, the method comprising administering to the HIV-infected mammal a protease inhibitor resistance-inhibiting effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein the protease inhibitor resistance-inhibiting effective amount is an amount sufficient to produce an in vivo protease inhibitor concentration or level in which a mutant virus that is capable of evolving from the HIV virus infecting the mammal has lower fitness, relative to the HIV virus infecting the mammal, in the presence of the compound, and\n",
            "wherein the method comprises further administration of at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: Oral suspension: 100 mg per mL (3)\n",
            "Tablets: 75 mg, 150 mg, 600 mg, and 800 mg (3)\n",
            "\n",
            "==same_claims_list: [114]\n",
            "********claim: \n",
            "13. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:3.\n",
            "\n",
            "==addition: Darunavir ethanolate has the following structural formula:\n",
            "Darunavir ethanolate is a white to off-white powder with a solubility of approximately 0.15 mg per mL in water at 20°C.\n",
            "\n",
            "==same_claims_list: [102, 72, 104, 74, 116]\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "********claim: \n",
            "1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "15. The composition of claim 3 wherein the ratio of the compound to water is about 1:0.5.\n",
            "\n",
            "==addition: PREZISTA 100 mg per mL oral suspension is available as a white to off-white opaque suspension for oral administration.\n",
            "\n",
            "==same_claims_list: [91, 92]\n",
            "********claim: \n",
            "12. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "==addition: Each mL of the oral suspension contains darunavir ethanolate equivalent to 100 mg darunavir.\n",
            "\n",
            "==same_claims_list: [63]\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: Each mL of the oral suspension contains darunavir ethanolate equivalent to 100 mg darunavir. In addition, each mL contains the inactive ingredients hydroxypropyl cellulose, microcrystalline cellulose, sodium carboxymethylcellulose, methylparaben sodium, citric acid monohydrate, sucralose, masking flavor, strawberry cream flavor, hydrochloric acid (for pH adjustment) and purified water.\n",
            "\n",
            "\n",
            "==same_claims_list: [104, 74, 72, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition: PREZISTA 75 mg tablets are available as white, caplet-shaped, film-coated tablets for oral administration.\n",
            "\n",
            "==same_claims_list: [49, 51, 55, 58, 31]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: Each 75 mg tablet contains darunavir ethanolate equivalent to 75 mg of darunavir.\n",
            "\n",
            "==same_claims_list: [49]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "==addition: PREZISTA 150 mg tablets are available as white, oval-shaped, film-coated tablets for oral administration.\n",
            "\n",
            "==same_claims_list: [49, 51, 53, 55, 58, 92, 31]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: \n",
            "PREZISTA 600 mg tablets are available as orange, oval-shaped, film-coated tablets for oral administration. \n",
            "\n",
            "==same_claims_list: [51, 53, 55, 58, 91, 92]\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "56. The method of claim 15, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "==addition: \n",
            "PREZISTA 800 mg tablets are available as dark red, oval-shaped, film-coated tablets for oral administration.\n",
            "\n",
            "==same_claims_list: [51, 53, 58, 91, 92, 31]\n",
            "********claim: \n",
            "52. The method of claim 13, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "54. The method of claim 14, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg–5 mg/kg of body weight.\n",
            "\n",
            "********claim: \n",
            "32. The method of claim 1, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.\n",
            "\n",
            "==addition: In addition, each mL contains the inactive ingredients citric acid monohydrate, hydrochloric acid (for pH adjustment), hydroxypropyl cellulose, masking flavor, methylparaben sodium, microcrystalline cellulose, purified water, sodium carboxymethylcellulose, strawberry cream flavor and sucralose.\n",
            "\n",
            "==same_claims_list: [104, 74, 72, 102]\n",
            "********claim: \n",
            "3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier.\n",
            "\n",
            "********claim: \n",
            "1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.\n",
            "\n",
            "********claim: \n",
            "1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.\n",
            "\n",
            "==addition: Each mL of the oral suspension contains darunavir 100 mg (present as darunavir ethanolate).\n",
            "\n",
            "==same_claims_list: [63]\n",
            "********claim: \n",
            "1. A method of treating a HIV-infected mammal who has developed resistance to HIV treatments, the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal an effective amount of a compound of the formula:\n",
            "\n",
            "\n",
            "\n",
            "wherein X is oxygen, R5 is isobutyl, and Ar is substituted phenyl; and\n",
            "(iii) administering at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir; whereby the HIV-infected mammal is treated.\n",
            "\n",
            "==addition: Each 75 mg tablet contains darunavir 75 mg (present as darunavir ethanolate).\n",
            "\n",
            "==same_claims_list: [49]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n",
            "==addition: Each 150 mg tablet contains darunavir 150 mg (present as darunavir ethanolate).\n",
            "\n",
            "==same_claims_list: [49]\n",
            "********claim: \n",
            "50. The method of claim 35, which comprises further administration of at least one other antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir, and saquinavir.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2eFxOAojoTLs",
        "outputId": "4f3af57e-3ab2-4080-d2e6-57c86fe9d9e2"
      },
      "source": [
        "i=1\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 171,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 22425\n",
            "==patents: ['8318800', '5223510', '9107900', '8410167', '7323493', '8602215']\n",
            "==addition: MULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14)].\n",
            "\n",
            "==same_claims_list: [64, 65, 96, 69, 44, 15, 49, 52, 58, 59]\n",
            "********claim: \n",
            "7. A method of treating a patient with a recent history of or current atrial fibrillation or flutter, said method comprising administrating to said patient a therapeutically effective amount of dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by: a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month, and (ii) wherein said atrial fibrillation or flutter is non-permanent and is paroxysmal or persistent; and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:\n",
            "i. an age greater than or equal to 75;\n",
            "ii. hypertension;\n",
            "iii. diabetes;\n",
            "iv. a history of cerebral stroke or of systemic embolism;\n",
            "v. a left atrial diameter greater than or equal to 50 mm; and\n",
            "vi. a left ventricular ejection fraction less than 40%.\n",
            "\n",
            "********claim: \n",
            "8. A method of decreasing a risk of hospitalization for atrial fibrillation in a patient having a history of atrial fibrillation or atrial flutter, said method comprising administering dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal to a patient in need thereof, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by: a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month, and (ii) wherein said atrial fibrillation or flutter is non-permanent and is paroxysmal or persistent; and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:\n",
            "i. an age greater than or equal to 75;\n",
            "ii. hypertension;\n",
            "iii. diabetes;\n",
            "iv. a history of cerebral stroke or of systemic embolism;\n",
            "v. a left atrial diameter greater than or equal to 50 mm; and\n",
            "vi. a left ventricular ejection fraction less than 40%.\n",
            "\n",
            "********claim: \n",
            "1. A method for managing the risk of dronedarone/beta-blocker interaction in a patient with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who is in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patient also expecting to receive a beta-blocker treatment, comprising administering dronedarone or a pharmaceutically acceptable salt thereof to said patient, and then performing the following steps:\n",
            "a—initiating beta-blocker treatment in said patient at a low dose;\n",
            "b—and then performing a electrocardiogram (ECG) assessment in said patient; and\n",
            "c—then increasing beta-blocker dose to said patient only if results in step b) verify good tolerability.\n",
            "\n",
            "********claim: \n",
            "12. The method according to claim 1, wherein said patient has a history of paroxysmal or persistent atrial fibrillation or atrial flutter.\n",
            "\n",
            "********claim: \n",
            "1. A method of reducing a risk of cardiovascular hospitalization in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by: a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month; and (ii) wherein said patient has a history of, or current, paroxysmal or persistent non-permanent atrial fibrillation or flutter, and (iii) wherein said patient has structural heart disease, wherein said structural heart disease is coronary heart disease; and (iv) wherein the patient has (a) an age greater than or equal to 75 or (b) an age greater than or equal to 70 and at least one cardiovascular risk factor selected from the group consisting of:\n",
            "i. hypertension;\n",
            "ii. diabetes;\n",
            "iii. a history of cerebral stroke or of systemic embolism;\n",
            "iv. a left atrial diameter greater than or equal to 50 mm; and\n",
            "v. a left ventricular ejection fraction less than 40%.\n",
            "\n",
            "********claim: \n",
            "1. Method for reducing mortality of cardiac origin, or nonfatal cardiac arrests effected by an arrhythmic event, in a patient having reduced left ventricular function after myocardial infarction, without rhythm disorders requiring antiarrhythmic treatment, comprising administering to said patient an effective amount of one or more active ingredients selected from the group consisting of benzofuran derivatives with antiarrhythmic activity and pharmaceutically acceptable salts, thereof, in combination with one or more pharmaceutically acceptable vehicles.\n",
            "\n",
            "********claim: \n",
            "6. A method of reducing a risk of cardiovascular hospitalization in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, twice a day with a morning and evening meal, (i) wherein said patient has a history of, or current, paroxysmal or persistent non-permanent atrial fibrillation or flutter; and (ii) wherein said patient has congestive heart failure defined as NYHA class III; and (iii) wherein said patient has not been hospitalized for heart failure within the last month.\n",
            "\n",
            "********claim: \n",
            "9. A method of reducing a risk of cardiovascular hospitalization for atrial fibrillation in a patient, said method comprising administering dronedarone, or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal to a patient in need of reduction of said risk, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by: a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month; and (ii) wherein said patient has a history of, or current, paroxysmal or persistent non-permanent atrial fibrillation, and (iii) wherein said patient has structural heart disease, wherein said structural heart disease is coronary heart disease; and (iv) wherein the patient has (a) an age greater than or equal to 75 or (b) an age greater than or equal to 70 and at least one cardiovascular risk factor selected from the group consisting of:\n",
            "i. hypertension;\n",
            "ii. diabetes;\n",
            "iii. a history of cerebral stroke or of systemic embolism;\n",
            "iv. a left atrial diameter greater than or equal to 50 mm; and\n",
            "v. a left ventricular ejection fraction less than 40%.\n",
            "\n",
            "********claim: \n",
            "1. A method of decreasing a risk of cardiovascular hospitalization in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, twice a day with a morning and an evening meal, wherein said patient does not have severe heart failure, (i) wherein severe heart failure is indicated by: a) NYHA Class IV heart failure or b) hospitalization for heart failure within the last month; and (ii) wherein said patient has a history of, or current, paroxysmal or persistent non-permanent atrial fibrillation or flutter; and (iii) wherein the patient has at least one cardiovascular risk factor selected from the group consisting of:\n",
            "i. an age greater than or equal to 75;\n",
            "ii. hypertension;\n",
            "iii. diabetes;\n",
            "iv. a history of cerebral stroke or of systemic embolism;\n",
            "v. a left atrial diameter greater than or equal to 50 mm; and\n",
            "vi. a left ventricular ejection fraction less than 40%.\n",
            "\n",
            "********claim: \n",
            "2. The method according to claim 1, wherein said cardiovascular hospitalization is hospitalization for atrial fibrillation.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qJPHWm4P025r",
        "outputId": "3004462a-8556-420f-9248-cf3086c758f7"
      },
      "source": [
        "i=2\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 172,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 18602\n",
            "==patents: ['3562257']\n",
            "==addition: Also contains: colloidal silicon dioxide, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake (30 mg and 90 mg), FD&C Yellow #6 Aluminum Lake (60 mg and 120 mg), hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, methylparaben, microcrystalline cellulose, and polyethylene glycol.\n",
            "\n",
            "==same_claims_list: [1]\n",
            "********claim: \n",
            "2. A process for obtaining an optically active salt of a cis-3-hydroxy-1,5-benzothiazepine compound of formula (I) from a racemic salt of the 1,5-benzothiazepine compound of formula (I): ##STR9## wherein each of Ring A and Ring B is a substituted or unsubstituted benzene ring, and R.sup.1 and R.sup.2 are the same or different and each is a lower alkyl group, the process comprising: dissolving a 1,5-benzothiazepine compound and 1-naphthalenesulfonic acid in an appropriate solvent under heating; cooling the solution; subjecting the resulting solution to preferential crystallization by obtaining a supersaturated solution of the racemic salt (I); inoculating seed crystals of a desired optically active salt of the corresponding (2S,3S)-isomer or the (2R,3R)-isomer into the solution to precipitate preferentially the same crystals as the inoculating salt; and collecting the precipitated crystals by filtration.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "a1sTkWpj1KwA",
        "outputId": "80911d54-fbe1-4819-f0dc-c644c680c9d8"
      },
      "source": [
        "i=3\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 173,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 208051\n",
            "==patents: ['8669273', '9630946', '10035788', '8518446', '9139558', '9211291', '8790708', '9265784', '7399865', '7982043']\n",
            "==addition: NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy [\n",
            "  see Clinical Studies (\n",
            "   14)\n",
            "  ].\n",
            "\n",
            "==same_claims_list: [0, 101, 103, 109, 142, 112, 115, 118, 22]\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine; wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "********claim: \n",
            "1. A regimen for treatment of early stage HER-2 positive breast cancer comprising delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "3. The regimen according to claim 1, wherein the cancer patients are treated with neratinib for at least about 12 months.\n",
            "\n",
            "********claim: \n",
            "9. A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-HER 2 positive ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in an early stage HER-2 positive breast cancer patient, said method comprising delivering neratinib to said patient following the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine.\n",
            "\n",
            "********claim: \n",
            "12. A regimen for improving invasive disease free survival, disease-free survival-HER 2 positive ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating early stage HER-2 positive breast cancer patients with neratinib for at least twelve months, wherein said treatment with neratinib following the completion of at least at least twelve cycles of adjuvant therapy with trastuzumab; and wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "15. The regimen according to claim 1, wherein the early stage HER-2 positive breast cancer patient is a hormone receptor positive patient.\n",
            "\n",
            "********claim: \n",
            "18. The regimen according to claim 17, wherein the early stage HER-2 positive breast cancer patient is an estrogen receptor or progesterone receptor positive patient.\n",
            "\n",
            "********claim: \n",
            "23. A method for treating an ErbB-2 positive metastatic breast cancer in a subject, wherein one treatment cycle comprises 21 days, comprising:\n",
            "(a) orally administering to the subject at least one unit dose of neratinib daily starting on day 1 of said cycle; and\n",
            "(b) orally administering to the subject at least one a unit dose of capecitabine on days 1 to 14 of said cycle;\n",
            "wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "==addition: NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy [\n",
            "  see Clinical Studies (\n",
            "   14)\n",
            "  ].\n",
            "\n",
            "==same_claims_list: [0, 101, 103, 109, 142, 112, 115, 118]\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine; wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "********claim: \n",
            "1. A regimen for treatment of early stage HER-2 positive breast cancer comprising delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "3. The regimen according to claim 1, wherein the cancer patients are treated with neratinib for at least about 12 months.\n",
            "\n",
            "********claim: \n",
            "9. A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-HER 2 positive ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in an early stage HER-2 positive breast cancer patient, said method comprising delivering neratinib to said patient following the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine.\n",
            "\n",
            "********claim: \n",
            "12. A regimen for improving invasive disease free survival, disease-free survival-HER 2 positive ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating early stage HER-2 positive breast cancer patients with neratinib for at least twelve months, wherein said treatment with neratinib following the completion of at least at least twelve cycles of adjuvant therapy with trastuzumab; and wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "15. The regimen according to claim 1, wherein the early stage HER-2 positive breast cancer patient is a hormone receptor positive patient.\n",
            "\n",
            "********claim: \n",
            "18. The regimen according to claim 17, wherein the early stage HER-2 positive breast cancer patient is an estrogen receptor or progesterone receptor positive patient.\n",
            "\n",
            "==addition: Inactive ingredients: Tablet Core: colloidal silicon dioxide, mannitol, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and purified water.\n",
            "\n",
            "==same_claims_list: [65, 131, 78, 82, 119]\n",
            "********claim: \n",
            "3. A pharmaceutically acceptable composition comprising intragranular components: (a) 10-70 weight percent of neratinib maleate; (b) 15-65 weight percent of mannitol, microcrystalline cellulose or a combination of both; (c) 0.5-8 weight percent crospovidone, croscarmellose sodium or a combination of both; (d) 0.2-8 weight percent colloidal silicon dioxide; and (e) 5-15 weight percent povidone; and extragranular components: (f) 1-25 weight percent of microcrystalline cellulose; (g) 1-8 weight percent of crospovidone; and (h) 0.5-3 weight percent of magnesium stearate.\n",
            "\n",
            "********claim: \n",
            "13. A pharmaceutical composition comprising:\n",
            "(A) intragranular components:\n",
            "(a) about 42.3 weight percent of neratinib maleate;\n",
            "(b) mannitol;\n",
            "(c) about 10.6 weight percent of microcrystalline cellulose;\n",
            "(d) about 3 weight percent of crospovidone;\n",
            "(e) about 2 weight percent of colloidal silicon dioxide; and\n",
            "(f) about 5 weight percent of povidone;\n",
            "\n",
            "(B) extragranular components:\n",
            "(g) about 1.5 weight percent of microcrystalline cellulose;\n",
            "(h) about 2 weight percent of crospovidone; and\n",
            "(i) about 2 weight percent of magnesium stearate; and\n",
            "\n",
            "(C) a film-coating.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutically acceptable composition of claim 3, comprising intragranular components: (a) 10-70 weight percent of neratinib maleate; (b) 15-65 weight percent of mannitol and microcrystalline cellulose; (c) 0.5-8 weight percent of crospovidone; (d) 0.2-8 weight percent of colloidal silicon dioxide; and (e) 5-15 weight percent of povidone; and extragranular components: (f) 1-25 weight percent of microcrystalline cellulose; (g) 1-8 weight percent of crospovidone; and (h) 0.5-3 weight percent of magnesium stearate.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the prepared neratinib maleate salt comprises crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate, monohydrate, Form II.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition comprising:\n",
            "(A) intragranular components:\n",
            "(a) about 35 weight percent of neratinib maleate measured in the amount of neratinib free base;\n",
            "(b) mannitol;\n",
            "(c) about 10.6 weight percent of microcrystalline cellulose;\n",
            "(d) about 3 weight percent of crospovidone;\n",
            "(e) about 2 weight percent of colloidal silicon dioxide; and\n",
            "(f) about 5 weight percent of povidone; and\n",
            "\n",
            "(B) extragranular components:\n",
            "(g) about 1.5 weight percent of microcrystalline cellulose;\n",
            "(h) about 2 weight percent of crospovidone; and\n",
            "(i) about 2 weight percent of magnesium stearate; and\n",
            "\n",
            "(C) a film-coating.\n",
            "\n",
            "==addition: Coating: red film coat: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.\n",
            "\n",
            "==same_claims_list: [128, 138]\n",
            "********claim: \n",
            "10. The pharmaceutical composition of claim 1, wherein the film-coating is a polyvinyl alcohol.\n",
            "\n",
            "********claim: \n",
            "20. The pharmaceutical composition of claim 13, wherein the film-coating is a polyvinyl alcohol.\n",
            "\n",
            "==addition: NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy [\n",
            "  see Clinical Studies (\n",
            "   14.1)\n",
            "  ].\n",
            "\n",
            "==same_claims_list: [0, 101, 75, 109, 142, 112, 115, 118, 22]\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine; wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "********claim: \n",
            "1. A regimen for treatment of early stage HER-2 positive breast cancer comprising delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "13. A method for treating cancer comprising administering an effective amount of a composition according to claim 1; wherein the cancer results from an aberrant tyrosine kinase receptor.\n",
            "\n",
            "********claim: \n",
            "9. A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-HER 2 positive ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in an early stage HER-2 positive breast cancer patient, said method comprising delivering neratinib to said patient following the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine.\n",
            "\n",
            "********claim: \n",
            "12. A regimen for improving invasive disease free survival, disease-free survival-HER 2 positive ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating early stage HER-2 positive breast cancer patients with neratinib for at least twelve months, wherein said treatment with neratinib following the completion of at least at least twelve cycles of adjuvant therapy with trastuzumab; and wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "15. The regimen according to claim 1, wherein the early stage HER-2 positive breast cancer patient is a hormone receptor positive patient.\n",
            "\n",
            "********claim: \n",
            "18. The regimen according to claim 17, wherein the early stage HER-2 positive breast cancer patient is an estrogen receptor or progesterone receptor positive patient.\n",
            "\n",
            "********claim: \n",
            "23. A method for treating an ErbB-2 positive metastatic breast cancer in a subject, wherein one treatment cycle comprises 21 days, comprising:\n",
            "(a) orally administering to the subject at least one unit dose of neratinib daily starting on day 1 of said cycle; and\n",
            "(b) orally administering to the subject at least one a unit dose of capecitabine on days 1 to 14 of said cycle;\n",
            "wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "==addition: NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting [ \n",
            "   see Clinical Studies ( \n",
            "    14.2) \n",
            "   ].\n",
            "\n",
            "==same_claims_list: [0, 101, 109, 142, 143, 112]\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine; wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "********claim: \n",
            "1. A regimen for treatment of early stage HER-2 positive breast cancer comprising delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "9. A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-HER 2 positive ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in an early stage HER-2 positive breast cancer patient, said method comprising delivering neratinib to said patient following the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine.\n",
            "\n",
            "********claim: \n",
            "2. The method according to claim 1, wherein the breast cancer is a locally advanced breast cancer.\n",
            "\n",
            "********claim: \n",
            "12. A regimen for improving invasive disease free survival, disease-free survival-HER 2 positive ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating early stage HER-2 positive breast cancer patients with neratinib for at least twelve months, wherein said treatment with neratinib following the completion of at least at least twelve cycles of adjuvant therapy with trastuzumab; and wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "==addition: NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting \n",
            "         .\n",
            "        NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting \n",
            "   [see Clinical Studies (\n",
            "    14.2)]\n",
            "   .\n",
            "\n",
            "==same_claims_list: [0, 101, 109, 142, 143, 112]\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine; wherein neratinib and capecitabine act synergistically.\n",
            "\n",
            "********claim: \n",
            "1. A regimen for treatment of early stage HER-2 positive breast cancer comprising delivering neratinib therapy to early stage HER-2 positive breast cancer patients at the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "9. A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-HER 2 positive ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in an early stage HER-2 positive breast cancer patient, said method comprising delivering neratinib to said patient following the completion of at least twelve cycles of trastuzumab adjuvant therapy; wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating an ErbB-2 positive metastatic breast cancer in a subject; comprising administering to the subject neratinib and capecitabine.\n",
            "\n",
            "********claim: \n",
            "2. The method according to claim 1, wherein the breast cancer is a locally advanced breast cancer.\n",
            "\n",
            "********claim: \n",
            "12. A regimen for improving invasive disease free survival, disease-free survival-HER 2 positive ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating early stage HER-2 positive breast cancer patients with neratinib for at least twelve months, wherein said treatment with neratinib following the completion of at least at least twelve cycles of adjuvant therapy with trastuzumab; and wherein the neratinib therapy is started about 2 weeks to about one year from the completion of surgical and standard adjuvant therapy.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "gObXk7R114Fm"
      },
      "source": [
        "The following is the result of a bad data grab.  All claims are group together as one unit in database.  Data grab is part of unrelated module."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gN6zTtPT1k1x",
        "outputId": "d64c54d7-6422-4198-c0b6-6086cf332690"
      },
      "source": [
        "i=4\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 174,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 21822-21882\n",
            "==patents: ['6596750']\n",
            "==addition:   In these patients, Exjade has been shown to reduce liver iron concentration and serum ferritin levels.  Clinical trials to demonstrate increased survival or to confirm clinical benefit have not been completed [see Clinical Studies (14)]. \n",
            "Individualize the decision to initiate Exjade therapy based on consideration of the anticipated clinical benefit and risks of the therapy, taking into consideration factors such as the life expectancy and comorbidities of the patient [see Warnings and Precautions (5.1- 5.6) and Contraindications (4)]. \n",
            "The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: An improvement in survival or disease-related symptoms has not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: \n",
            "Limitation of Use\n",
            "The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.  This indication is based on a reduction of liver iron concentrations and serum ferritin levels [see Clinical Studies (14)]. An improvement in survival or disease related symptoms has not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. This indication is based on achievement of an LIC less than 5 mg Fe/g dw [see Clinical Studies (14)]. An improvement in survival or disease-related symptoms has not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. This indication is based on achievement of an LIC less than 5 mg Fe/g dw [see Clinical Studies (14)]. An improvement in survival or disease-related symptoms has not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Controlled clinical trials of Exjade with myelodysplastic syndromes (MDS) and chronic iron overload due to blood transfusions have not been performed [see Clinical Studies (14)].\n",
            "The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Its molecular formula is C21H15N3O4 and its molecular weight is 373.4 g/mol.\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "==addition: Inactive Ingredients: Crospovidone (NF), lactose monohydrate (NF), magnesium stearate (NF), microcrystalline cellulose (NF), povidone (K30) (NF), silicon dioxide (NF), and sodium lauryl sulphate (NF).\n",
            "\n",
            "==same_claims_list: [0]\n",
            "********claim: \n",
            "1. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in which\n",
            "R1 and R5 simultaneously or independently of one another are hydrogen, halogen, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, carboxyl, carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylcarbamoyl or nitrile; \n",
            "R2 and R4 simultaneously or independently of one another are hydrogen, unsubstituted or substituted lower alkanoyl or aroyl, or a protective group; \n",
            "R3 is hydrogen, lower alkyl, hydroxy-lower alkyl, halo-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, R6R7N—C(O)-lower alkyl, unsubstituted or substituted aryl or aryl-lower alkyl, or unsubstituted or substituted heteroaryl or heteroaralkyl; \n",
            "R6 and R7 simultaneously or independently of one another are hydrogen, lower alkyl, hydroxy-lower alkyl, alkoxy-lower alkyl, hydroxyalkoxy-lower alkyl, amino-lower alkyl, N-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkyl, N-(hydroxy-lower alkyl)amino-lower alkyl, N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "2. The method according to claim 1 wherein the metal is iron.\n",
            "\n",
            "\n",
            "3. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted or substituted lower alkanoyl or aroyl; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; unsubstituted or substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl, with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "4. The method according to claim 3 wherein a compound of formula (II) is administered in each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy;\n",
            "each of R2 and R4, independently, is hydrogen; or a protective group; \n",
            "R3 is R6R7N—C(O)-lower alkyl; substituted aryl; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkyl amino or pyrrolidino; or unsubstituted or substituted heteroaryl or heteroaralkyl with the proviso that R3 is not phenyl or phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, halo-lower alkyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "5. The method according to claim 3 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "R2 and R4 are hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; aryl-lower alkyl substituted by N-lower alkylamino, N,N-di-lower alkylamino or pyrrolidino; or unsubstituted or substituted heteroaralkyl; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; N,N-di(hydroxy-lower alkyl)amino-lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "each of R8 and R9, independently, is hydrogen; lower alkyl or, together with the nitrogen atom to which they are bonded, form an azaalicyclic ring; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "6. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}-(4-methylpiperazin-1-yl)methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]phenyl}morpholin-4-ylmethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-yl-ethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazole-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "7. The method according to claim 3 wherein the metal is iron.\n",
            "\n",
            "\n",
            "8. A method of treating iron overload comprising administering a subject in need of such treatment a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "9. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula (II) \n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; carboxyl; carbamoyl; N-lower alkylcarbamoyl; N,N-di-lower-alkylcarbamoyl; or nitrile; \n",
            "each of R2 and R4, independently, is hydrogen; unsubstituted lower alkanoyl; lower alkanoyl substituted by halogen, hydroxyl, lower alkoxy, trifluoromethyl, cyclo-lower alkyl or phenyl; unsubstituted aroyl; or aroyl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R2 and R4 are hydrogen, and R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy or nitrile; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "10. The method of claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; lower alkyl; halo-lower alkyl; lower alkoxy; or halo-lower alkoxy; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by one or two substituents selected from lower alkyl, lower alkoxy, hydroxyl, nitro, halogen, trifluoromethyl, carboxyl, lower alkoxycarbonyl, amino, N-lower alkylamino, N,N-di-lower alkylamino, aminocarbonyl, lower alkylaminocarbonyl, di-lower alkylaminocarbonyl and nitrile; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "with the proviso that\n",
            "R3 is not phenyl substituted by halogen, nitro, nitrile, hydroxyl, lower alkyl, trifluoromethyl, lower alkoxy or lower alkoxycarbonyl if R1 and R5 are hydrogen, halogen, lower alkyl, halo-lower alkyl or lower alkoxy; and \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "11. The method according to claim 9 wherein a compound of formula (II) is administered in which\n",
            "each of R1 and R5, independently, is hydrogen; halogen; or lower alkyl; \n",
            "each of R2 and R4 is hydrogen; \n",
            "R3 is R6R7N—C(O)-lower alkyl; aryl substituted by carboxyl or R8R9N—C(O)—; or aryl-lower alkyl substituted by N-lower alkylamino or N,N-di-lower alkylamino; \n",
            "each of R6 and R7, independently, is hydrogen; lower alkyl; hydroxy-lower alkyl; alkoxy-lower alkyl; hydroxyalkoxy-lower alkyl; amino-lower alkyl; N-lower alkylamino-lower alkyl; N,N-di-lower alkylamino-lower alkyl; N-(hydroxy-lower alkyl)amino-lower alkyl; or N,N-di(hydroxy-lower alkyl)amino-lower alkyl; and \n",
            "each of R8 and R9, independently, is hydrogen or lower alkyl; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "12. The method according to claim 9 wherein the compound which is administered is selected from the group consisting of:\n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-dimethylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-dihydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; and \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "13. The method according to claim 9 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "14. The method according to claim 9 wherein the compound which is administered is 2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "15. The method according to claim 9 wherein the metal is iron.\n",
            "\n",
            "\n",
            "16. A method of treating iron overload comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula II, as claimed in claim 9, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "17. The method according to claim 16 wherein the compound which is administered is 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, or a pharmaceutically acceptable salt thereof.\n",
            "\n",
            "\n",
            "18. A method of treating diseases which cause an excess of metal in a human or animal body or are caused by an excess of metal in a human or animal body comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of:\n",
            "3,5-bis(2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; ethyl[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-nitrophenyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}morpholin-4-yl-methanone; \n",
            "{4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-phenyl}-(4-methylpiperazin-1-yl)-methanone; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(2,4-difluorophenyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-benzyl-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-ylmethyl]benzonitrile; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-diethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(4-pyrrolidin-1-ylbenzyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-4-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(2-hydroxyphenyl)-1-(pyridin-3-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(2-hydroxyethyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(pyridin-2-ylmethyl)-1H-[1,2,4]triazole; \n",
            "3,5-bis(5-chloro-2-hydroxyphenyl)-1-(4-dimethylaminobenzyl)-1H-[1,2,4]triazole; \n",
            "4-[3,5-bis(5-fluoro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "4-[3,5-bis(2-hydroxy-5-methylphenyl)-[1,2,4]triazol-1-yl]benzoic acid; \n",
            "[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetic acid; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-methoxyethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2,3-di-hydroxypropyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-hydroxyethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(2-hydroxyethoxy)ethyl]-acetamide; \n",
            "N-{2-[bis(2-hydroxyethyl)amino]ethyl}-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-hydroxy-1-hydroxymethylethyl)acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-[2-(4-methylpiperazin-1-yl)-ethyl]acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-di-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-morpholin-4-ylethanone; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-1-(4-methylpiperazin-1-yl)-ethanone; \n",
            "N-benzyl-2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-methylacetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N,N-bis(2-hydroxyethyl)-acetamide; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-dimethylaminoethyl)-N-methylacetamide; \n",
            "2-[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-N-(2-morpholin-4-yl-ethyl)acetamide; \n",
            "ethyl[3,5-bis(5-chloro-2-hydroxyphenyl)-[1,2,4]triazol-1-yl]acetate; \n",
            "2-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid; and \n",
            "ethyl-4-(3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoate; \n",
            "or a pharmaceutically acceptable salt thereof.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "WhMZE8ML1zsD",
        "outputId": "ba936c41-93d5-4f8b-e277-eada448ce833"
      },
      "source": [
        "i=5\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 175,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 22517\n",
            "==patents: ['7560429', '7947654', '9504647', '9974826', '10137167', '9919025', '10307459', '8802624', '9220747']\n",
            "==addition: It is chemically defined as follows:\n",
            "Molecular weight of 1183.34 with the following empirical formula:\n",
            "   C\n",
            "  46H\n",
            "  64N\n",
            "  14O\n",
            "  12S\n",
            "  2∙C\n",
            "  2H\n",
            "  4O\n",
            "  2∙3H\n",
            "  2O\n",
            "1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.\n",
            "\n",
            "==same_claims_list: [108, 76, 14, 53, 62]\n",
            "********claim: \n",
            "1. An orodispersible pharmaceutical dosage form of desmopressin comprising:\n",
            "desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and\n",
            "one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,\n",
            "wherein the dosage form exhibits a mean elimination half-life of desmopressin after administration of about 2.8 to 3 hours after the maximum plasma concentration is reached.\n",
            "\n",
            "********claim: \n",
            "3. The method according to claim 1, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n",
            "********claim: \n",
            "15. An orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form (i) disintegrates in the mouth within 10 seconds, (ii) comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 μg, 50 μg and 75 μg, and (iii) is prepared by a process comprising subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in the solvent, wherein the composition is in the solid state in a mold.\n",
            "\n",
            "********claim: \n",
            "8. The method according to claim 1, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n",
            "********claim: \n",
            "17. The method according to claim 13, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n",
            "==addition: It is chemically defined as follows:\n",
            "Molecular weight of 1183.34 with the following empirical formula: C46H64N14O12S2∙C2H4O2∙3H2O\n",
            "1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.\n",
            "\n",
            "==same_claims_list: [76, 108, 14, 21, 53, 118, 61, 62]\n",
            "********claim: \n",
            "3. The method according to claim 1, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n",
            "********claim: \n",
            "1. An orodispersible pharmaceutical dosage form of desmopressin comprising:\n",
            "desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and\n",
            "one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,\n",
            "wherein the dosage form exhibits a mean elimination half-life of desmopressin after administration of about 2.8 to 3 hours after the maximum plasma concentration is reached.\n",
            "\n",
            "********claim: \n",
            "15. An orodispersible solid pharmaceutical dosage form of desmopressin acetate, wherein said dosage form (i) disintegrates in the mouth within 10 seconds, (ii) comprises an amount of desmopressin, measured as the free base, selected from the group consisting of 25 μg, 50 μg and 75 μg, and (iii) is prepared by a process comprising subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in the solvent, wherein the composition is in the solid state in a mold.\n",
            "\n",
            "********claim: \n",
            "3. The dosage form as claimed in claim 1, wherein the dosage form is obtainable by subliming solvent from a composition comprising desmopressin acetate and a solution of carrier material in a solvent, the composition being in the solid state in a mold.\n",
            "\n",
            "********claim: \n",
            "8. The method according to claim 1, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n",
            "********claim: \n",
            "11. An orodispersible pharmaceutical dosage form of desmopressin comprising:\n",
            "desmopressin in a form selected from one or more of the free base of desmopressin and a pharmaceutically acceptable salt thereof, in an amount measured as the free base, selected from 25 μg and 50 μg, and\n",
            "one or more carriers, wherein at least one carrier is gelatin in an open matrix network structure,\n",
            "wherein the dosage form exhibits a desmopressin bioavailability of from 0.23% to 0.38%.\n",
            "\n",
            "********claim: \n",
            "16. The method according to claim 13, wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin.\n",
            "\n",
            "********claim: \n",
            "17. The method according to claim 13, wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7VLHubYb2DpY",
        "outputId": "a735a6bb-8bdf-45d4-c752-43032070ce0b"
      },
      "source": [
        "i=6\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 176,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 20785\n",
            "==patents: ['8315886', '7874984', '8626531', '7959566', '6561977', '7230012', '7435745', '8143283', '6869399', '7141018', '6561976', '8589188', '7723361', '6908432', '8204763']\n",
            "==addition: Chemical Structure of thalidomide\n",
            "Thalidomide is an off-white to white, odorless, crystalline powder that is soluble at 25°C in dimethyl sulfoxide and sparingly soluble in water and ethanol.\n",
            "\n",
            "==same_claims_list: [116, 111]\n",
            "********claim: \n",
            "6. The method of claim 1, wherein the epoxide hydrolase inhibitor is administered to said human together with thalidomide.\n",
            "\n",
            "********claim: \n",
            "1. A method for inhibiting undesired angiogenesis in a human having a blood born tumor comprising orally administering to said human a capsule comprising an angiogenesis-inhibiting amount of thalidomide and administering an amount of a compound that is an epoxide hydrolase inhibitor.\n",
            "\n",
            "==addition: Multiple Myeloma\n",
            "THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma.\n",
            "The effectiveness of THALOMID® (thalidomide) is based on response rates (See\n",
            "CLINICAL STUDIES \n",
            "section.) There are no controlled trials demonstrating a clinical benefit, such as an improvement in survival.\n",
            "\n",
            "==same_claims_list: [75, 67, 77, 53]\n",
            "********claim: \n",
            "3. A method for treating leukemia in a patient having leukemia comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to §aid patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating blood-borne tumors comprising administering to a patient in need of such treatment an effective amount of thalidomide in combination with dexamethasone.\n",
            "\n",
            "********claim: \n",
            "5. A method of treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering a capsule of thalidomide to said patient, wherein said patient is administered an anti-angiogenic amount of 0.5 to 50 mg/kg/day of thalidomide as an anti-angiogenic agent against said tumor.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 1 further comprising providing the patient, prior to generation of the approval code, with warnings of the side effects associated with administration of thalidomide, wherein said side effects are non-teratogenic side effects.\n",
            "\n",
            "==addition: THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).\n",
            "\n",
            "==same_claims_list: [67, 71, 73, 75, 77]\n",
            "********claim: \n",
            "1. A method of treating blood-borne tumors comprising administering to a patient in need of such treatment an effective amount of thalidomide in combination with dexamethasone.\n",
            "\n",
            "********claim: \n",
            "5. The method of claim 1, wherein the thalidomide and dexamethasone are administered parenterally.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to said patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "3. A method for treating leukemia in a patient having leukemia comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to §aid patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "5. A method of treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering a capsule of thalidomide to said patient, wherein said patient is administered an anti-angiogenic amount of 0.5 to 50 mg/kg/day of thalidomide as an anti-angiogenic agent against said tumor.\n",
            "\n",
            "==addition: THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).\n",
            "THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. \n",
            "THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.\n",
            "\n",
            "==same_claims_list: [67, 73, 75, 77, 78, 16, 53]\n",
            "********claim: \n",
            "1. A method of treating blood-borne tumors comprising administering to a patient in need of such treatment an effective amount of thalidomide in combination with dexamethasone.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to said patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "3. A method for treating leukemia in a patient having leukemia comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to §aid patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "5. A method of treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering a capsule of thalidomide to said patient, wherein said patient is administered an anti-angiogenic amount of 0.5 to 50 mg/kg/day of thalidomide as an anti-angiogenic agent against said tumor.\n",
            "\n",
            "********claim: \n",
            "1. A method for treating erythema nodosum leprosum using thalidomide while restricting access to thalidomide for patients for whom thalidomide may be contraindicated, said method comprising permitting prescriptions for thalidomide to be filled by a pharmacy only after the pharmacy has received an approval code for the prescription from a computer readable storage medium, wherein generation of the prescription approval code comprises the following steps:\n",
            "a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for thalidomide; \n",
            "b. defining a set of information to be obtained from the patient, which information is probative of the risk that an adverse side effect is likely to occur if thalidomide is taken by the patient; \n",
            "c. in response to the information set, assigning the patient to at least one of the risk groups and entering the patient, the information and the patient's risk group assignment into the medium; \n",
            "d. based upon the information and the risk group assignment, determining whether the risk that the adverse side effect is likely to occur is acceptable; and \n",
            "e. upon a determination that the risk is acceptable, generating the prescription approval code to be received by the pharmacy before the prescription is filled.\n",
            "\n",
            "********claim: \n",
            "6. The system of claim 4, wherein the drug is a teratogen intended for prescription for activity selected from the group comprising: disease diagnosis; disease cure; disease mitigation; disease treatment or prevention; and to affect the structure or function of the body of the patient.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 1 further comprising providing the patient, prior to generation of the approval code, with warnings of the side effects associated with administration of thalidomide, wherein said side effects are non-teratogenic side effects.\n",
            "\n",
            "==addition: THALOMID 50 mg, 100 mg, 150 mg and 200 mg capsules will be supplied through the S.T.E.P.S.®\n",
            "  program [see How Supplied/Storage and Handling (16)].\n",
            "THALOMID is available in the following capsule strengths:\n",
            "50 mg capsules [white opaque], imprinted “Celgene/50 mg” with a “Do Not Get Pregnant” logo.\n",
            "\t\t\t\t\t\t\t100 mg capsules [tan], imprinted “Celgene/100 mg” with a “Do Not Get Pregnant” logo.\n",
            "\t\t\t\t\t\t\t150 mg capsules [tan and blue], imprinted “Celgene/150 mg” with a “Do Not Get Pregnant” logo\n",
            "\t\t\t\t\t\t200 mg capsule [blue], imprinted “Celgene/200 mg” with a “Do not Get Pregnant” logo.\n",
            "\n",
            "==same_claims_list: [113, 69]\n",
            "********claim: \n",
            "3. The method of claim 2 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the amount of thalidomide administered is from 0.5 to 50 mg/kg/day.\n",
            "\n",
            "==addition: THALOMID, α-(N-phthalimido) glutarimide, is an immunomodulatory agent. The empirical formula for thalidomide is C13H10N2O4 and the gram molecular weight is 258.2. The CAS number of thalidomide is 50-35-1.\n",
            "                                  Chemical Structure of Thalidomide\n",
            "Thalidomide is an off-white to white, odorless, crystalline powder that is soluble at 25°C in dimethyl sulfoxide and sparingly soluble in water and ethanol. The glutarimide moiety contains a single asymmetric center and, therefore, may exist in either of two optically active forms designated S-(-) or R-(+). THALOMID is an equal mixture of the S-(-) and R-(+) forms and, therefore, has a net optical rotation of zero.\n",
            "THALOMID is available in 50 mg, 100 mg, 150 mg and 200 mg capsules for oral administration. Active ingredient: thalidomide. Inactive ingredients: pregelatinized starch and magnesium stearate. The 50 mg capsule shell contains gelatin, titanium dioxide, and black ink. The 100 mg capsule shell contains black iron oxide, yellow iron oxide, titanium dioxide, gelatin, and black ink. The 150 mg capsule shell contains FD&C blue #2, black iron oxide, yellow iron oxide, titanium dioxide, gelatin, and black and white ink. The 200 mg capsule shell contains FD&C blue #2, titanium dioxide, gelatin, and white ink.\n",
            "\n",
            "==same_claims_list: [68, 69, 112, 113, 61]\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the amount of thalidomide administered is from 0.1 to 300 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the amount of thalidomide administered is from 0.5 to 50 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "5. A single unit dosage form in the form of a size 2 capsule, the contents of which weighs 250 mg, and comprising 100 mg of thalidomide and pregelatinized corn starch.\n",
            "\n",
            "==addition: THALOMID 50 mg, 100 mg, 150 mg and 200 mg capsules will be supplied through the THALOMID REMSTM program [see How Supplied/Storage and Handling (16)].\n",
            "\n",
            "==same_claims_list: [68, 69, 70, 74, 76, 112, 113, 114, 61, 63]\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the amount of thalidomide administered is from 0.1 to 300 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the amount of thalidomide administered is from 0.5 to 50 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "4. The method of claim 3, wherein the amount of thalidomide administered is from 1 to 10 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "4. The method of claim 3 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "4. The method of claim 3 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.\n",
            "\n",
            "********claim: \n",
            "5. A single unit dosage form in the form of a size 2 capsule, the contents of which weighs 250 mg, and comprising 100 mg of thalidomide and pregelatinized corn starch.\n",
            "\n",
            "********claim: \n",
            "7. A single unit dosage form in the form of a size 0 capsule comprising a uniform admixture of 200 mg of thalidomide and 297.5 mg of pregelatinized corn starch.\n",
            "\n",
            "==addition: THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1)].\n",
            "\n",
            "==same_claims_list: [73, 75, 67, 77]\n",
            "********claim: \n",
            "1. A method for treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to said patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "3. A method for treating leukemia in a patient having leukemia comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to §aid patient wherein said thalidomide is administered in a capsule.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating blood-borne tumors comprising administering to a patient in need of such treatment an effective amount of thalidomide in combination with dexamethasone.\n",
            "\n",
            "********claim: \n",
            "5. A method of treating a blood-born tumor in a patient having a blood-born tumor comprising orally administering a capsule of thalidomide to said patient, wherein said patient is administered an anti-angiogenic amount of 0.5 to 50 mg/kg/day of thalidomide as an anti-angiogenic agent against said tumor.\n",
            "\n",
            "==addition: THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2)].\n",
            "\n",
            "==same_claims_list: [67]\n",
            "********claim: \n",
            "1. A method of treating blood-borne tumors comprising administering to a patient in need of such treatment an effective amount of thalidomide in combination with dexamethasone.\n",
            "\n",
            "==addition: Capsules:\n",
            "50 mg white, printed with \"Celgene/50 mg\" on the body and a \"Do Not Get Pregnant\" logo on the cap.\n",
            "100 mg tan, printed with \"Celgene/100 mg\" on the body and a \"Do Not Get Pregnant\" logo on the cap.\n",
            "\n",
            "==same_claims_list: [61]\n",
            "********claim: \n",
            "5. A single unit dosage form in the form of a size 2 capsule, the contents of which weighs 250 mg, and comprising 100 mg of thalidomide and pregelatinized corn starch.\n",
            "\n",
            "==addition: 100 mg tan, printed with \"Celgene/100 mg\" on the body and a \"Do Not Get Pregnant\" logo on the cap.\n",
            "150 mg tan body printed with \"Celgene/150 mg\" and blue cap printed with a \"Do Not Get Pregnant\" logo.\n",
            "\n",
            "==same_claims_list: [61]\n",
            "********claim: \n",
            "5. A single unit dosage form in the form of a size 2 capsule, the contents of which weighs 250 mg, and comprising 100 mg of thalidomide and pregelatinized corn starch.\n",
            "\n",
            "==addition: Chemical Structure of Thalidomide\n",
            "Note: ∙ = asymmetric carbon atom\n",
            "Thalidomide is an off-white to white, odorless, crystalline powder that is soluble at 25°C in dimethyl sulfoxide and sparingly soluble in water and ethanol.\n",
            "\n",
            "==same_claims_list: [116, 111]\n",
            "********claim: \n",
            "6. The method of claim 1, wherein the epoxide hydrolase inhibitor is administered to said human together with thalidomide.\n",
            "\n",
            "********claim: \n",
            "1. A method for inhibiting undesired angiogenesis in a human having a blood born tumor comprising orally administering to said human a capsule comprising an angiogenesis-inhibiting amount of thalidomide and administering an amount of a compound that is an epoxide hydrolase inhibitor.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3neoj3r12W0l",
        "outputId": "6a184e73-dfea-4933-90fb-51e8a5d10c09"
      },
      "source": [
        "i=7\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 177,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 205831\n",
            "==patents: ['10039719', '9801823', '7438930', '9066869', '7247318', '8580310', '7083808']\n",
            "==addition: APTENSIO XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [\n",
            "see Clinical Studies (14)].\n",
            "\n",
            "==same_claims_list: [74]\n",
            "********claim: \n",
            "20. A method of treating Attention Deficit Hyperactivity Disorder in a child comprising: administering to the child once-a-day in the morning a formulation according to claim 1.\n",
            "\n",
            "==addition: APTENSIO XR contains methylphenidate hydrochloride, a central nervous system (CNS) stimulant.\n",
            "\n",
            "==same_claims_list: [1]\n",
            "********claim: \n",
            "2. The method of claim 1, wherein said formulation comprises methylphenidate hydrochloride.\n",
            "\n",
            "==addition:  \n",
            "Inactive Ingredients: ammonio methacrylate copolymer, type B; colloidal silicon dioxide (added if necessary); gelatin; hypromelloses; methacrylic acid copolymer, type C; polyethylene glycol; sugar spheres; talc; titanium oxide; and triethyl citrate.\n",
            "\n",
            "==same_claims_list: [77, 100, 45]\n",
            "********claim: \n",
            "3. The formulation of claim 1, wherein a unit dose comprises said plurality of substrates contained within a gelatin capsule, and said remaining portion of said methylphenidate or pharmaceutically acceptable salt thereof is contained within said gelatin capsule in a form selected from the group consisting of an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, and as a coating applied onto the surface of said enteric coated substrates.\n",
            "\n",
            "********claim: \n",
            "7. The oral dosage form of claim 1, wherein the pH dependent release modifying coating is selected from the group consisting of shellac, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, a pH dependent methacrylic acid ester copolymer and zein.\n",
            "\n",
            "********claim: \n",
            "2. The formulation of claim 1, wherein a unit dose comprises the matrix particulates contained within a gelatin capsule, and the second portion of the methyiphenidate or pharmaceutically acceptable salt thereof is contained within the gelatin capsule in a form selected from the group consisting of an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, and as a coating applied onto the surface of the enteric coated matrix particulates.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PCQywRTS3UwG",
        "outputId": "d1eb7c03-85b8-45cb-dfa9-7ae33c1d3df5"
      },
      "source": [
        "i=8\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 178,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 209241\n",
            "==patents: ['10857148', '8039627', '10906903', '10952997', '10919892', '10912771', '10851103', '8357697', '10940141', '10851104', '10874648', '10065952', '10906902', '10844058', '10857137']\n",
            "==addition: INGREZZA capsules are available in the following strengths:\n",
            "40 mg capsules with a white opaque body and purple cap, printed with ‘VBZ’ and ‘40’ in black ink.\n",
            "\n",
            "==same_claims_list: [163, 8, 176, 17, 124, 125]\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the first amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "==addition: INGREZZA capsules are available in the following strengths:\n",
            "40 mg capsules with a white opaque body and purple cap, printed with ‘VBZ’ and ‘40’ in black ink.\n",
            "80 mg capsules with a purple opaque body and cap, printed with ‘VBZ’ and ‘80’ in black ink.\n",
            "\n",
            "==same_claims_list: [165, 176, 17, 18, 124, 125]\n",
            "********claim: \n",
            "4. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the first amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 16, wherein the second amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "==addition: 80 mg capsules with a purple opaque body and cap, printed with ‘VBZ’ and ‘80’ in black ink.\n",
            "\n",
            "==same_claims_list: [176, 18, 124, 166]\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 16, wherein the second amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week.\n",
            "\n",
            "********claim: \n",
            "5. The method of claim 1, wherein the VMAT2 inhibitor is administered in the form of a tablet or capsule.\n",
            "\n",
            "==addition: Each capsule contains valbenazine tosylate equivalent to 40 or 80 mg of valbenazine free base.\n",
            "\n",
            "==same_claims_list: [12, 14, 17, 18, 21, 23, 163, 165, 180, 181, 182, 188, 317, 190, 191, 327, 74, 124, 125, 127]\n",
            "********claim: \n",
            "13. The method of claim 12, wherein the VMAT2 inhibitor is administered in an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 12, wherein the VMAT2 inhibitor is administered in an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the first amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 16, wherein the second amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "22. The method of claim 21, wherein the therapeutically effective amount of the VMAT2 inhibitor is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "24. The method of claim 21, wherein the therapeutically effective amount of the VMAT2 inhibitor is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "4. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 14, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "20. The method of claim 14, wherein the therapeutically effective amount is an amount equivalent to about 60 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "21. The method of claim 14, wherein the therapeutically effective amount is an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "27. A method of treating a patient with tardive dyskinesia, comprising:\n",
            "administering a vesicular monoamine transporter 2 (VMAT2) inhibitor chosen from (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester and pharmaceutically acceptable salts thereof to the patient, wherein the patient is administered an initial dose of the VMAT2 inhibitor in an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week;\n",
            "subsequently determining that the patient has severe renal impairment; and\n",
            "continuing administering a therapeutically effective amount of the VMAT2 inhibitor to the patient.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 17, wherein the therapeutically effective amount is an amount equivalent to about 80 mg once daily as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 27, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "30. The method of claim 27, wherein the therapeutically effective amount is an amount equivalent to about 80 mg, of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 27, wherein the increased amount is an amount equivalent to about 80 mg once daily as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the therapeutically effective amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "==addition: The capsule shells contain gelatin, candurin silver fine, FD&C Red#40, and FD&C Blue#1.\n",
            "\n",
            "==same_claims_list: [234]\n",
            "********claim: \n",
            "10. A pharmaceutical composition comprising the crystal form of claim 1 and a pharmaceutically acceptable carrier.\n",
            "\n",
            "==addition: The capsule shells contain gelatin, candurin silver fine, FD&C Red#40, and FD&C Blue#1. \n",
            "Table 3\n",
            "\tContents of INGREZZA\n",
            "Presentation\n",
            "Inactive Ingredients \n",
            "INGREZZA 40 mg, Size 1 capsule\n",
            "Colloidal silicon dioxide, magnesium stearate, mannitol, pregelatinized starch\n",
            "INGREZZA 40 mg, Size 2 capsuleINGREZZA 80 mg, Size 1 capsule\n",
            "Hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose\n",
            "\n",
            "==same_claims_list: [205, 214]\n",
            "********claim: \n",
            "14. The process according to claim 1, wherein crystalline Form I of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester tosylate salt has an X-ray powder diffraction (XRPD) pattern comprising a peak at a two-theta angle of 6.3°±0.2°.\n",
            "\n",
            "********claim: \n",
            "23. Crystalline Form I of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester tosylate salt prepared according to claim 1.\n",
            "\n",
            "==addition: Table 3\n",
            "\tContents of INGREZZA\n",
            "Presentation\n",
            "Inactive Ingredients \n",
            "INGREZZA 40 mg, Size 1 capsule\n",
            "Colloidal silicon dioxide, magnesium stearate, mannitol, pregelatinized starch\n",
            "INGREZZA 40 mg, Size 2 capsuleINGREZZA 80 mg, Size 1 capsule\n",
            "Hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose\n",
            "\n",
            "==same_claims_list: [128, 205, 215]\n",
            "********claim: \n",
            "1. A crystalline form of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester tosylate salt having a differential scanning calorimetric (DSC) onset temperature within 2% of 240° C.\n",
            "\n",
            "********claim: \n",
            "14. The process according to claim 1, wherein crystalline Form I of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester tosylate salt has an X-ray powder diffraction (XRPD) pattern comprising a peak at a two-theta angle of 6.3°±0.2°.\n",
            "\n",
            "********claim: \n",
            "24. Crystalline Form I of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester tosylate salt prepared according to claim 18.\n",
            "\n",
            "==addition: Each capsule contains 73 mg or 146 mg of valbenazine tosylate equivalent to 40 mg or 80 mg of valbenazine free base, respectively.\n",
            "\n",
            "==same_claims_list: [163, 164, 165, 327, 73, 74, 127, 18, 188, 180, 125, 316, 21, 124, 317, 190, 191]\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 60 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "4. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 27, wherein the increased amount is an amount equivalent to about 80 mg once daily as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the therapeutically effective amount is an amount equivalent to about 60 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the therapeutically effective amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 16, wherein the second amount is an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "27. A method of treating a patient with tardive dyskinesia, comprising:\n",
            "administering a vesicular monoamine transporter 2 (VMAT2) inhibitor chosen from (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester and pharmaceutically acceptable salts thereof to the patient, wherein the patient is administered an initial dose of the VMAT2 inhibitor in an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week;\n",
            "subsequently determining that the patient has severe renal impairment; and\n",
            "continuing administering a therapeutically effective amount of the VMAT2 inhibitor to the patient.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 14, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "13. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 15, wherein the therapeutically effective amount is an amount equivalent to about 60 mg once daily as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.\n",
            "\n",
            "********claim: \n",
            "22. The method of claim 21, wherein the therapeutically effective amount of the VMAT2 inhibitor is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester once daily.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 1, wherein the therapeutically effective amount is an amount equivalent to about 40 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily for one week, and an amount equivalent to about 80 mg as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily after one week.\n",
            "\n",
            "********claim: \n",
            "19. The method of claim 17, wherein the therapeutically effective amount is an amount equivalent to about 80 mg once daily as measured by (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.\n",
            "\n",
            "********claim: \n",
            "29. The method of claim 27, wherein the therapeutically effective amount is an amount equivalent to about 40 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n",
            "********claim: \n",
            "30. The method of claim 27, wherein the therapeutically effective amount is an amount equivalent to about 80 mg, of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hZ_TNA893Wyh",
        "outputId": "0361ae3b-ab58-424b-e1d0-6bbdcbd9a474"
      },
      "source": [
        "i=9\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 179,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 21964-208271\n",
            "==patents: ['10376505', '9492445', '10376584', '9180125', '8822490', '6559158', '9314461', '8524276', '10307417', '8956651', '8420663', '8552025', '9669096', '9724343', '8247425']\n",
            "==addition: \n",
            "Limitation of use: Use of RELISTOR beyond four months has not been studied in the advanced illness population.\n",
            "\n",
            "==same_claims_list: [145, 355, 47]\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "31. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 24 months at about room temperature.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 16, wherein the subject is a cancer patient.\n",
            "\n",
            "==addition: Single-use vial containing 12 mg/0.6 mL solution for subcutaneous injection, for use with a 27 gauge x 1⁄2-inch needle and 1 mL syringe\n",
            "Single-use vial containing 12 mg/0.6 mL solution for subcutaneous injection, with one 1 mL syringe with retractable 27 gauge x 1⁄2-inch needle, two alcohol swabs\n",
            "Single-use pre-filled syringe containing 8 mg/0.4 mL solution for subcutaneous injection, with a 29-gauge x 1⁄2-inch fixed needle and a needle guard\n",
            "Single-use pre-filled syringe containing 12 mg/0.6 mL solution for subcutaneous injection, with a 29-gauge x 1⁄2-inch fixed needle and a needle guard\n",
            "\n",
            "==same_claims_list: [388, 390, 392, 41, 425, 427, 415, 315, 401, 411, 86, 283, 412, 413, 414, 95]\n",
            "********claim: \n",
            "5. The prefilled syringe according to claim 1, comprising 8 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "7. The prefilled syringe according to claim 1, comprising 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "12. The composition of claim 1, wherein the package is selected from the group consisting of: a syringe, a vial and an ampoule.\n",
            "\n",
            "********claim: \n",
            "42. The prefilled syringe of claim 39, wherein compound II-1 is present in an amount of less than 125 ppm.\n",
            "\n",
            "********claim: \n",
            "44. The prefilled syringe of claim 39, wherein compound II-1 is present in an amount of less than 25 ppm.\n",
            "\n",
            "********claim: \n",
            "32. The prefilled syringe of claim 27, wherein the liquid composition comprises less than about 25 ppm of the compound of formula II-1.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical preparation of claim 13, wherein the solution is provided in a vial with a septum or in a syringe.\n",
            "\n",
            "********claim: \n",
            "18. The prefilled syringe of claim 15, wherein the liquid composition comprises less than about 125 ppm of the compound of formula II.\n",
            "\n",
            "********claim: \n",
            "28. The prefilled syringe of claim 27, wherein the liquid composition comprises less than about 185 ppm of the compound of formula II-1.\n",
            "\n",
            "********claim: \n",
            "3. The packaged composition of claim 1, wherein the packaged composition comprises a syringe, a vial, a sachet or an ampoule.\n",
            "\n",
            "********claim: \n",
            "11. The method of claim 1, wherein the packaged composition is selected from the group consisting of a syringe, a vial, a sachet and an ampoule.\n",
            "\n",
            "********claim: \n",
            "29. The prefilled syringe of claim 27, wherein the liquid composition comprises less than about 150 ppm of the compound of formula II-1.\n",
            "\n",
            "********claim: \n",
            "30. The prefilled syringe of claim 27, wherein the liquid composition comprises less than about 125 ppm of the compound of formula II-1.\n",
            "\n",
            "********claim: \n",
            "31. The prefilled syringe of claim 27, wherein the liquid composition comprises less than about 100 ppm of the compound of formula II-1.\n",
            "\n",
            "********claim: \n",
            "12. The method of claim 11, wherein the packaged composition comprises a syringe, a vial, a sachet or an ampoule.\n",
            "\n",
            "==addition: RELISTOR (methylnaltrexone bromide) injection, a peripherally-acting mu-opioid receptor antagonist, is a sterile, clear and colorless to pale yellow aqueous solution.\n",
            "\n",
            "==same_claims_list: [229, 325, 10, 50, 146, 20, 213, 219, 188, 349]\n",
            "********claim: \n",
            "17. The pharmaceutical composition of claim 14, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "11. The pharmaceutical composition of claim 3, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) and an amphiphilic pharmaceutically acceptable excipient comprising a saturated or unsaturated, branched or unbranched, cyclic or acyclic C4-30 aliphatic group that is optionally substituted, wherein when the methylnaltrexone, or the pharmaceutically acceptable salt thereof, and the amphiphilic pharmaceutically acceptable excipient are in solution, the apparent octanol/water partition coefficient for methylnaltrexone is at least 0.25 at a pH between 1 and 4.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "7. The pharmaceutical composition of claim 1, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "3. The pharmaceutical composition of claim 2, wherein the ion pair is formed when the methylnaltrexone, or a pharmaceutically acceptable salt thereof, and sodium dodecyl sulfate (SDS) are dissolved in solution at a pH of greater than about 1 and less than about 4.\n",
            "\n",
            "********claim: \n",
            "25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.\n",
            "\n",
            "==addition: RELISTOR is indicated for the treatment of opioid-induced constipation in adult patients with chronic non‐cancer pain.\n",
            "\n",
            "==same_claims_list: [393, 145, 274, 275, 279, 280, 281, 289, 299, 44, 45, 46, 300, 301, 57, 58, 78, 79, 80, 96, 379, 380, 381]\n",
            "********claim: \n",
            "10. The method according to claim 9, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "7. The method of claim 5, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "8. The method of claim 7, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the subject is receiving opioids chronically.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 1, wherein the subject is receiving an opioid at a morphine equivalent dose of between about 30 and about 100 oral mg/day of methadone.\n",
            "\n",
            "********claim: \n",
            "27. A method of treating opioid induced constipation in a subject, comprising administering to the subject a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "contained within a packaged composition substantially free of tungsten; wherein the packaged composition comprises less than about 190 ppm of a compound of formula II:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the subject receives an opioid chronically.\n",
            "\n",
            "********claim: \n",
            "28. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III-1 is administered with a syringe that is substantially free of tungsten; wherein the syringe comprises less than about 190 ppm of a compound of formula II\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "29. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III is administered with a syringe that is substantially free of tungsten, wherein A− is a suitable anion; and\n",
            "wherein the syringe comprises less than about 190 ppm of a compound of formula II:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "9. A method for treating an opioid-induced peripheral side effect comprising administering to a patient the stable pharmaceutical preparation of claim 1 in an amount effective to treat the side effect.\n",
            "\n",
            "********claim: \n",
            "10. The method of claim 9, wherein the opioid induced peripheral side effect is constipation.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 14, wherein the subject receives opioids chronically.\n",
            "\n",
            "********claim: \n",
            "13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "16. A method for treating a gastrointestinal disorder in a subject comprising administering the composition of claim 1.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 17, wherein the constipation is opioid-induced.\n",
            "\n",
            "==addition: RELISTOR is indicated for the treatment of opioid-induced constipation in adult patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. \n",
            "Limitation of Use                                            \n",
            "Use of RELISTOR beyond four months has not been studied in the advanced illness population.\n",
            "\n",
            "==same_claims_list: [393, 145, 274, 275, 279, 280, 281, 299, 44, 45, 46, 300, 301, 57, 58, 78, 79, 80, 96, 380, 381]\n",
            "********claim: \n",
            "10. The method according to claim 9, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "7. The method of claim 5, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "8. The method of claim 7, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the subject is receiving opioids chronically.\n",
            "\n",
            "********claim: \n",
            "27. A method of treating opioid induced constipation in a subject, comprising administering to the subject a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "contained within a packaged composition substantially free of tungsten; wherein the packaged composition comprises less than about 190 ppm of a compound of formula II:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the subject receives an opioid chronically.\n",
            "\n",
            "********claim: \n",
            "28. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III-1 is administered with a syringe that is substantially free of tungsten; wherein the syringe comprises less than about 190 ppm of a compound of formula II\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "29. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III is administered with a syringe that is substantially free of tungsten, wherein A− is a suitable anion; and\n",
            "wherein the syringe comprises less than about 190 ppm of a compound of formula II:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "9. A method for treating an opioid-induced peripheral side effect comprising administering to a patient the stable pharmaceutical preparation of claim 1 in an amount effective to treat the side effect.\n",
            "\n",
            "********claim: \n",
            "10. The method of claim 9, wherein the opioid induced peripheral side effect is constipation.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 14, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 14, wherein the subject receives opioids chronically.\n",
            "\n",
            "********claim: \n",
            "13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 17, wherein the constipation is opioid-induced.\n",
            "\n",
            "==addition: RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection is indicated for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.\n",
            "\n",
            "==same_claims_list: [96, 289, 0, 281, 393, 45, 46, 79, 80, 145, 274, 275, 213, 280, 57, 58, 380, 381]\n",
            "********claim: \n",
            "13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 1, wherein the subject is receiving an opioid at a morphine equivalent dose of between about 30 and about 100 oral mg/day of methadone.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the subject is receiving opioids chronically.\n",
            "\n",
            "********claim: \n",
            "10. The method according to claim 9, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the subject receives an opioid chronically.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 14, wherein the subject receives opioids chronically.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "8. The method of claim 7, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "9. A method for treating an opioid-induced peripheral side effect comprising administering to a patient the stable pharmaceutical preparation of claim 1 in an amount effective to treat the side effect.\n",
            "\n",
            "********claim: \n",
            "10. The method of claim 9, wherein the opioid induced peripheral side effect is constipation.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 17, wherein the constipation is opioid-induced.\n",
            "\n",
            "==addition: RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, a mu-opioid receptor antagonist, is a sterile, clear and colorless to pale yellow aqueous solution.\n",
            "\n",
            "==same_claims_list: [229, 325, 10, 302, 242, 50, 20, 213, 146, 219, 349]\n",
            "********claim: \n",
            "17. The pharmaceutical composition of claim 14, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "11. The pharmaceutical composition of claim 3, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof, wherein the preparation comprises a pH between about 3.0 and about 4.0.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) an amphiphilic pharmaceutically acceptable excipient, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and an anion of the amphiphilic pharmaceutically acceptable excipient based upon the total weight of the composition and wherein the composition in solution has an apparent octanol/water partition coefficient for methylnaltrexone of at least 0.25 at a pH between 1 and 4.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) and an amphiphilic pharmaceutically acceptable excipient comprising a saturated or unsaturated, branched or unbranched, cyclic or acyclic C4-30 aliphatic group that is optionally substituted, wherein when the methylnaltrexone, or the pharmaceutically acceptable salt thereof, and the amphiphilic pharmaceutically acceptable excipient are in solution, the apparent octanol/water partition coefficient for methylnaltrexone is at least 0.25 at a pH between 1 and 4.\n",
            "\n",
            "********claim: \n",
            "7. The pharmaceutical composition of claim 1, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.\n",
            "\n",
            "==addition: RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.\n",
            "\n",
            "==same_claims_list: [393, 145, 274, 275, 279, 280, 281, 289, 299, 300, 45, 46, 57, 58, 79, 80, 96, 380, 381]\n",
            "********claim: \n",
            "10. The method according to claim 9, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "2. The method of claim 1, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "7. The method of claim 5, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "8. The method of claim 7, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the subject is receiving opioids chronically.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 1, wherein the subject is receiving an opioid at a morphine equivalent dose of between about 30 and about 100 oral mg/day of methadone.\n",
            "\n",
            "********claim: \n",
            "27. A method of treating opioid induced constipation in a subject, comprising administering to the subject a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "contained within a packaged composition substantially free of tungsten; wherein the packaged composition comprises less than about 190 ppm of a compound of formula II:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "28. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III-1 is administered with a syringe that is substantially free of tungsten; wherein the syringe comprises less than about 190 ppm of a compound of formula II\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the subject receives an opioid chronically.\n",
            "\n",
            "********claim: \n",
            "9. A method for treating an opioid-induced peripheral side effect comprising administering to a patient the stable pharmaceutical preparation of claim 1 in an amount effective to treat the side effect.\n",
            "\n",
            "********claim: \n",
            "10. The method of claim 9, wherein the opioid induced peripheral side effect is constipation.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 14, wherein the subject receives opioids chronically.\n",
            "\n",
            "********claim: \n",
            "13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the gastrointestinal disorder is constipation.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 17, wherein the constipation is opioid-induced.\n",
            "\n",
            "==addition: RELISTOR injection is indicated for the treatment of OIC in adult patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.\n",
            "\n",
            "==same_claims_list: [96, 281, 393, 300, 45, 46, 79, 80, 145, 275, 280, 57, 58, 381, 287]\n",
            "********claim: \n",
            "13. The method according to claim 11, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "9. The method of claim 1, wherein the subject is receiving opioids chronically.\n",
            "\n",
            "********claim: \n",
            "10. The method according to claim 9, wherein the subject is suffering from opioid induced constipation.\n",
            "\n",
            "********claim: \n",
            "28. A method of treating constipation in a subject, comprising administering to the subject a unit dosage of a compound of formula III-1\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula III-1 is administered with a syringe that is substantially free of tungsten; wherein the syringe comprises less than about 190 ppm of a compound of formula II\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein X− is a suitable anion.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 16, wherein the subject receives an opioid chronically.\n",
            "\n",
            "********claim: \n",
            "16. The method of claim 15, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 14, wherein the subject receives opioids chronically.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "3. The method of claim 2, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "8. The method of claim 7, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "9. A method for treating an opioid-induced peripheral side effect comprising administering to a patient the stable pharmaceutical preparation of claim 1 in an amount effective to treat the side effect.\n",
            "\n",
            "********claim: \n",
            "10. The method of claim 9, wherein the opioid induced peripheral side effect is constipation.\n",
            "\n",
            "********claim: \n",
            "18. The method of claim 17, wherein the constipation is opioid-induced.\n",
            "\n",
            "********claim: \n",
            "15. The method of claim 6, wherein the compound of formula III is administered by injection or infusion.\n",
            "\n",
            "==addition: Limitations of Use\n",
            "Use of RELISTOR injection beyond four months has not been studied in the advanced illness population.\n",
            "\n",
            "==same_claims_list: [363, 145, 355]\n",
            "********claim: \n",
            "39. The stable pharmaceutical preparation of claim 38, wherein about 1% or less methylnaltrexone degradation products form following 3 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "31. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 24 months at about room temperature.\n",
            "\n",
            "==addition: Tablets:\n",
            "1.150 mg methylnaltrexone bromide supplied as film-coated, white, round, biconvex, debossed with “REL” on one side and plain on the other side.\n",
            "\n",
            "==same_claims_list: [0, 15, 20, 22, 29, 50, 186, 63, 213, 344, 226, 231, 362, 236, 237, 238, 239, 240, 241]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "23. The pharmaceutical composition of claim 1 made with methylnaltrexone bromide and sodium dodecyl sulfate in a ratio of about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "15. The pharmaceutical preparation of claim 1, wherein the methylnaltrexone or salt thereof is methylnaltrexone bromide and is at a concentration of about 20 mg/mL, and wherein the EDTA or a derivative thereof is at a concentration of about 0.1 to about 2.5 mg/ml.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "20. The pharmaceutical preparation of claim 1, wherein the preparation comprises a solution of methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "19. The pharmaceutical composition of claim 1 made with methylnaltrexone bromide and sodium dodecyl sulfate in a ratio of about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "38. The stable pharmaceutical preparation of claim 25, wherein the methylnaltrexone or salt thereof is methylnaltrexone bromide and is at a concentration of about 20 mg/mL, wherein the EDTA or a derivative thereof is at a concentration of about 0.3 to about 0.5 mg/ml, wherein the solution has a pH of about 3.5.\n",
            "\n",
            "********claim: \n",
            "24. The pharmaceutical composition of claim 14, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "25. The pharmaceutical composition of claim 24, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "********claim: \n",
            "26. The pharmaceutical composition of claim 17, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "27. The pharmaceutical composition of claim 26, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "********claim: \n",
            "28. The pharmaceutical composition of claim 19, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "29. The pharmaceutical composition of claim 28, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "==addition: Tablets:\n",
            "1.150 mg methylnaltrexone bromide supplied as film-coated, white, round, biconvex, debossed with “REL” on one side and plain on the other side.\n",
            "Injection:\n",
            "Single-dose Vial: \n",
            "2.12 mg/0.6 mL methylnaltrexone bromide supplied as colorless to pale yellow solution. \n",
            "\n",
            "==same_claims_list: [0, 226, 389, 325, 229, 236, 237, 238, 15, 240, 50, 213, 349, 29]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "17. The pharmaceutical composition of claim 14, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "24. The pharmaceutical composition of claim 14, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "25. The pharmaceutical composition of claim 24, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "********claim: \n",
            "26. The pharmaceutical composition of claim 17, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "28. The pharmaceutical composition of claim 19, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "==addition: \n",
            "Single-dose Pre-filled Syringe: \n",
            "3.8 mg/0.4 mL methylnaltrexone bromide supplied as colorless to pale yellow solution.\n",
            "\n",
            "==same_claims_list: [388, 389, 325, 391, 392, 213]\n",
            "********claim: \n",
            "5. The prefilled syringe according to claim 1, comprising 8 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "==addition: \n",
            "Single-dose Pre-filled Syringe: \n",
            "3.8 mg/0.4 mL methylnaltrexone bromide supplied as colorless to pale yellow solution.\n",
            "4.12 mg/0.6 mL methylnaltrexone bromide supplied as colorless to pale yellow solution.\n",
            "\n",
            "==same_claims_list: [0, 325, 389, 391, 392, 302, 213, 349, 29, 94]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof, wherein the preparation comprises a pH between about 3.0 and about 4.0.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "********claim: \n",
            "11. A method comprising the steps of: (i) providing a packaged composition, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of a compound of formula III-1:\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and a compound of formula II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula II-1 is present in an amount of less than about 190 ppm; and (ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "==addition: RELISTOR® (methylnaltrexone bromide) is a mu-opioid receptor antagonist.\n",
            "\n",
            "==same_claims_list: [0, 289, 226, 229, 10, 236, 238, 15, 49, 50, 242, 20, 22, 344, 219, 349]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "17. The method of claim 1, wherein the subject is receiving an opioid at a morphine equivalent dose of between about 30 and about 100 oral mg/day of methadone.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "17. The pharmaceutical composition of claim 14, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "11. The pharmaceutical composition of claim 3, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "24. The pharmaceutical composition of claim 14, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "26. The pharmaceutical composition of claim 17, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent; wherein the chelating agent is ethylenediaminetriacetic acid (EDTA) or a derivative thereof.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) an amphiphilic pharmaceutically acceptable excipient, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and an anion of the amphiphilic pharmaceutically acceptable excipient based upon the total weight of the composition and wherein the composition in solution has an apparent octanol/water partition coefficient for methylnaltrexone of at least 0.25 at a pH between 1 and 4.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "23. The pharmaceutical composition of claim 1 made with methylnaltrexone bromide and sodium dodecyl sulfate in a ratio of about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "20. The pharmaceutical preparation of claim 1, wherein the preparation comprises a solution of methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "7. The pharmaceutical composition of claim 1, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "25. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, EDTA or a derivative thereof, wherein the solution has a pH from about 3.0 to 4.0, and wherein the methylnaltrexone or salt thereof is the sole pharmaceutical active agent.\n",
            "\n",
            "==addition: The structural formula is: \n",
            "RELISTOR tablets for oral administration are film-coated and contain 150 mg of methylnaltrexone bromide (equivalent to 122.5 mg methylnaltrexone). Inactive ingredients are silicified microcrystalline cellulose, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, crospovidone, poloxamer 407, stearic acid (vegetable source), colloidal silicon dioxide, edetate calcium disodium, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc. \n",
            "RELISTOR for subcutaneous administration is a sterile, clear and colorless to pale yellow aqueous solution. \n",
            "\n",
            "==same_claims_list: [0, 226, 4, 229, 10, 219, 15, 242, 20, 213, 186, 187, 29]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "5. The pharmaceutical composition of claim 3, wherein the rapid-acting disintegrant is sodium bicarbonate.\n",
            "\n",
            "********claim: \n",
            "17. The pharmaceutical composition of claim 14, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "11. The pharmaceutical composition of claim 3, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "7. The pharmaceutical composition of claim 1, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) an amphiphilic pharmaceutically acceptable excipient, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and an anion of the amphiphilic pharmaceutically acceptable excipient based upon the total weight of the composition and wherein the composition in solution has an apparent octanol/water partition coefficient for methylnaltrexone of at least 0.25 at a pH between 1 and 4.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "2. The pharmaceutical composition of claim 1, wherein the methylnaltrexone, or a pharmaceutically acceptable salt thereof, and sodium dodecyl sulfate (SDS) form an ion pair when dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "==addition: Each 3 mL vial contains 12 mg of methylnaltrexone bromide (equivalent to 9.8 mg of methylnaltrexone) in 0.6 mL of water.\n",
            "\n",
            "==same_claims_list: [389, 39, 391, 295, 72, 213, 91, 93]\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "10. The composition of claim 8, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "23. The method of claim 6, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "9. The composition of claim 6, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "8. The packaged composition according to claim 7, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "10. The packaged composition according to claim 9, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "==addition: Each 8 mg/0.4 mL pre-filled syringe (1 mL syringe) contains 8 mg of methylnaltrexone bromide (equivalent to 6.5 mg of methylnaltrexone)in 0.4 mL of water.\n",
            "\n",
            "==same_claims_list: [388, 389, 38, 39, 392, 391, 70, 293]\n",
            "********claim: \n",
            "5. The prefilled syringe according to claim 1, comprising 8 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "9. The composition of claim 8, wherein the solution comprises about 8 mg of the compound of formula III in about 0.4 mL water.\n",
            "\n",
            "********claim: \n",
            "10. The composition of claim 8, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "7. The composition of claim 6, wherein the solution comprises about 8 mg of the compound of formula III in about 0.4 mL water.\n",
            "\n",
            "********claim: \n",
            "21. The method of claim 6, wherein the solution comprises about 8 mg of the compound of formula III in about 0.4 mL water.\n",
            "\n",
            "==addition: Each 12 mg/0.6 mL pre-filled syringe (1 mL syringe) contains 12 mg of methylnaltrexone bromide (equivalent to 9.8 mg of methylnaltrexone) in 0.6 mL of water.\n",
            "\n",
            "==same_claims_list: [389, 390, 391, 392, 39, 295, 72, 213, 91, 94]\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "7. The prefilled syringe according to claim 1, comprising 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "10. The composition of claim 8, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "23. The method of claim 6, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "9. The composition of claim 6, wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "8. The packaged composition according to claim 7, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "11. A method comprising the steps of: (i) providing a packaged composition, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of a compound of formula III-1:\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and a compound of formula II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula II-1 is present in an amount of less than about 190 ppm; and (ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "==addition: o\n",
            "Injection:\n",
            "o\n",
            "Single-dose Vial: \n",
            "•12 mg/0.6 mL methylnaltrexone bromide supplied as colorless to pale yellow solution.\n",
            "\n",
            "==same_claims_list: [0, 389, 390, 325, 392, 213, 29, 94]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "7. The prefilled syringe according to claim 1, comprising 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "********claim: \n",
            "11. A method comprising the steps of: (i) providing a packaged composition, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of a compound of formula III-1:\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and a compound of formula II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula II-1 is present in an amount of less than about 190 ppm; and (ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "==addition: o\n",
            "Single-dose Pre-filled Syringe: \n",
            "•8 mg/0.4 mL methylnaltrexone bromide supplied as colorless to pale yellow solution.\n",
            "\n",
            "==same_claims_list: [388, 389, 325, 391, 392, 94]\n",
            "********claim: \n",
            "5. The prefilled syringe according to claim 1, comprising 8 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm.\n",
            "\n",
            "********claim: \n",
            "6. The prefilled syringe according to claim 5, wherein the liquid composition further comprises 2.6 mg sodium chloride, 0.16 mg edetate calcium disodium, and 0.12 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "1. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof and a chelating agent consisting of EDTA, or a derivative thereof, wherein the solution has a pH ranging from about 3.0 to 4.0.\n",
            "\n",
            "********claim: \n",
            "8. The prefilled syringe according to claim 7, wherein the liquid composition further comprises 3.9 mg sodium chloride, 0.24 mg edetate calcium disodium, and 0.18 mg glycine hydrochloride.\n",
            "\n",
            "********claim: \n",
            "9. A method comprising the steps of:\n",
            "(i) providing a prefilled syringe, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of compound III-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and compound II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein compound II-1 is present in an amount of less than about 190 ppm; and\n",
            "(ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "********claim: \n",
            "11. A method comprising the steps of: (i) providing a packaged composition, substantially free from tungsten, comprising a unit dosage of a liquid composition comprising 8 mg or 12 mg of a compound of formula III-1:\n",
            "\n",
            "\n",
            "\n",
            "in 0.4 mL or 0.6 mL water, and a compound of formula II-1:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "wherein the compound of formula II-1 is present in an amount of less than about 190 ppm; and (ii) administering the unit dosage to a subject via subcutaneous injection.\n",
            "\n",
            "==addition:  \n",
            "Limitations of Use\n",
            "Use of RELISTOR injection beyond four months has not been studied in the advanced illness population.\n",
            "\n",
            "==same_claims_list: [363, 145, 355]\n",
            "********claim: \n",
            "39. The stable pharmaceutical preparation of claim 38, wherein about 1% or less methylnaltrexone degradation products form following 3 months stored at about room temperature, relative to the total methylnaltrexone present in the solution.\n",
            "\n",
            "********claim: \n",
            "1. A method of preventing or treating an opioid-induced side effect in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, wherein said amount is insufficient to treat the side effect in a patient to whom opioids have not been chronically administered and wherein said amount is such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "2. The method of claim 1 wherein the quaternary derivative is methylnaltrexone.\n",
            "\n",
            "\n",
            "3. The method of claim 2 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "4. The method of claim 2 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "5. The method of claim 2 wherein the methylnaltrexone is enterically coated.\n",
            "\n",
            "\n",
            "6. The method of claim 2 wherein the methylnaltrexone is administered in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "7. The method of claim 6 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "8. The method of claim 2 wherein the methylnaltrexone is administered at a dosage of about 0.001 to about 5 mg/kg body weight.\n",
            "\n",
            "\n",
            "9. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 3 mg/kg body weight.\n",
            "\n",
            "\n",
            "10. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 1 mg/kg body weight.\n",
            "\n",
            "\n",
            "11. The method of claim 2 wherein the methylnaltrexone is administered at a dose of less than about 0.1 mg/kg body weight.\n",
            "\n",
            "\n",
            "12. The method of claim 2 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "13. The method of claim 2 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "14. The method of claim 2 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "15. The method of claim 2 wherein the methylnaltrexone is administered orally.\n",
            "\n",
            "\n",
            "16. The method of claim 15 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "17. The method of claim 15 therein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "\n",
            "18. The method of claim 15 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "19. The method of claim 15 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "20. The method of claim 2 wherein the methylnaltrexone is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "21. The method of claim 1 wherein the side effect to be prevented or treated is constipation.\n",
            "\n",
            "\n",
            "22. The method of claim 1 wherein the side effect is selected from the group consisting of dysphoria, pruritus, and urinary retention.\n",
            "\n",
            "\n",
            "23. The method of claim 1, wherein the opioid and the quaternary derivative of noroxymorphone are combined in an oral dose.\n",
            "\n",
            "\n",
            "24. The method of claim 23 wherein the quaternary derivative is enterically coated.\n",
            "\n",
            "\n",
            "25. The method of claim 1 wherein the quaternary derivative is administered orally in a form that is not enterically coated.\n",
            "\n",
            "\n",
            "26. The method of claim 1 wherein the quaternary derivative is administered orally.\n",
            "\n",
            "\n",
            "27. The method of claim 26 wherein the quaternary derivative is administered orally in a form that is enterically coated.\n",
            "\n",
            "\n",
            "28. The method of claim 1 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "29. The method of claim 1 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "30. The method of claim 1 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "31. A method of preventing or treating opioid-induced constipation, the method comprising:\n",
            "determining how long the patient has been administered opioids; \n",
            "selecting a dose of a quaternary derivative of noroxymorphone based on the length of time the patient has been administered opioids, wherein the dose selected for a chronic opioid patient is at least 10% lower than the dose selected for a patient not chronically administered opioids, and wherein the dose is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml; and \n",
            "administering the selected dose of the quaternary derivative of noroxymorphone to the patient. \n",
            "\n",
            "\n",
            "32. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 20% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "33. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 30% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "34. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 50% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "35. The method of claim 31 wherein the dose selected for a patient chronically administered opioids is at least 70% lower than the dose selected for a patient not chronically administered opioids.\n",
            "\n",
            "\n",
            "36. A method of preventing or reducing constipation in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the constipation in the patient, wherein said amount is not sufficient to reduce the constipation in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "37. A method of preventing or reducing urinary retention in a chronic opioid patient, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or reduce the urinary retention in the patient, where said amount is not sufficient to reduce the urinary retention in a patient to whom opioids have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "38. A method of preventing or reducing dysphoria in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the dysphoria in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "39. A method of preventing or reducing pruritus in a chronic opioid patient, the method comprising administering a quaternary derivative or noroxymorphane in an amount sufficient to prevent or reduce the dysphoria in the patient, wherein said amount is not sufficient to reduce the pruritus in a patient to whom opiods have not been chronically administered, and wherein said amount is administered in an amount such that peak plasma concentrations do not exceed 100 ng/ml.\n",
            "\n",
            "\n",
            "40. The method of any of claims 31, 36, 37, 38, or 39 wherein the peak plasma concentrations do not exceed 50 ng/ml.\n",
            "\n",
            "\n",
            "41. The method of claim 40 wherein the peak plasma concentrations do not exceed 20 ng/ml.\n",
            "\n",
            "\n",
            "42. The method of claim 40 wherein the peak plasma concentrations do not exceed 10 ng/ml.\n",
            "\n",
            "\n",
            "43. The method of claim 31 or 36 wherein the peak plasma concentrations do not exceed 26 ng/ml.\n",
            "\n",
            "********claim: \n",
            "31. The pharmaceutical preparation of claim 26, wherein the pharmaceutical preparation is stable to storage for 24 months at about room temperature.\n",
            "\n",
            "==addition: Tablets:\n",
            "1.150 mg methylnaltrexone bromide supplied as film-coated, white, round, biconvex, debossed with “REL” on one side and plain on the other side.\n",
            "\n",
            "==same_claims_list: [0, 15, 20, 22, 29, 50, 186, 63, 213, 344, 226, 231, 362, 236, 237, 238, 239, 240, 241]\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "16. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "21. The pharmaceutical composition of claim 16, wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.\n",
            "\n",
            "********claim: \n",
            "23. The pharmaceutical composition of claim 1 made with methylnaltrexone bromide and sodium dodecyl sulfate in a ratio of about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "30. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the composition comprises about 7% to about 75% of methylnaltrexone cation and dodecyl sulfate anion, based upon total weight of the composition; and wherein the composition further comprises\n",
            "(a) a chelating agent comprising calcium EDTA disodium;\n",
            "(b) a binder comprising microcrystalline cellulose;\n",
            "(c) a glidant comprising colloidal silicon dioxide; and\n",
            "(d) magnesium stearate and talc.\n",
            "\n",
            "********claim: \n",
            "2. The stable pharmaceutical preparation of claim 1, wherein the preparation comprises methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone, or a pharmaceutically acceptable salt thereof, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion, based upon the total weight of the composition.\n",
            "\n",
            "********claim: \n",
            "15. The pharmaceutical preparation of claim 1, wherein the methylnaltrexone or salt thereof is methylnaltrexone bromide and is at a concentration of about 20 mg/mL, and wherein the EDTA or a derivative thereof is at a concentration of about 0.1 to about 2.5 mg/ml.\n",
            "\n",
            "********claim: \n",
            "1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide, and (ii) sodium dodecyl sulfate (SDS), wherein the composition is a tablet, wherein methylnaltrexone bromide is the sole active agent, wherein the tablet is not enterically coated, and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.\n",
            "\n",
            "********claim: \n",
            "20. The pharmaceutical preparation of claim 1, wherein the preparation comprises a solution of methylnaltrexone bromide.\n",
            "\n",
            "********claim: \n",
            "14. The pharmaceutical composition of claim 1, wherein the ratio of methylnaltrexone bromide to sodium dodecyl sulfate in the tablet is about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "19. The pharmaceutical composition of claim 1 made with methylnaltrexone bromide and sodium dodecyl sulfate in a ratio of about 3:1 by weight.\n",
            "\n",
            "********claim: \n",
            "38. The stable pharmaceutical preparation of claim 25, wherein the methylnaltrexone or salt thereof is methylnaltrexone bromide and is at a concentration of about 20 mg/mL, wherein the EDTA or a derivative thereof is at a concentration of about 0.3 to about 0.5 mg/ml, wherein the solution has a pH of about 3.5.\n",
            "\n",
            "********claim: \n",
            "24. The pharmaceutical composition of claim 14, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "25. The pharmaceutical composition of claim 24, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "********claim: \n",
            "26. The pharmaceutical composition of claim 17, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "27. The pharmaceutical composition of claim 26, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n",
            "********claim: \n",
            "28. The pharmaceutical composition of claim 19, wherein the amount of methylnaltrexone bromide is about 150 mg.\n",
            "\n",
            "********claim: \n",
            "29. The pharmaceutical composition of claim 28, wherein the amount of methylnaltrexone bromide is 150 mg and the amount of sodium dodecyl sulfate (SDS) is 50 mg.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RNp0WHdm3Yk9",
        "outputId": "ccf09be5-22f7-4178-9e04-9f68ca0dfd96"
      },
      "source": [
        "i=10\n",
        "NDA=random_NDA_list[i]\n",
        "\n",
        "print_top_percentage_multi(multi_return_match_result, NDA, \"additions_with_context\", \"patents\")"
      ],
      "execution_count": 180,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "==NDA: 22406\n",
            "==patents: ['9415053', '7592339', '7157456', '9539218', '7585860', '10828310']\n",
            "==addition: XARELTO is indicated for the prophylaxis of venous thromboembolism (VTE) and VTE related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and not at high risk of bleeding [see Warnings and Precautions (5.2) and Clinical Studies (14.5)].\n",
            "\n",
            "==same_claims_list: [16, 40, 75]\n",
            "********claim: \n",
            "17. A method for the prophylaxis and/or treatment of thromboembolic diseases comprising administering an effective amount of the pharmaceutical composition of claim 6 to a patient in need thereof.\n",
            "\n",
            "********claim: \n",
            "17. A method for treating a disorder selected from the group consisting of myocardial infarct, unstable angina, stroke, transitory ischaemic attacks, peripheral arterial occlusive disorders, pulmonary embolisms and deep venous thromboses comprising administering an effective amount of a compound of formula:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "or a hydrate thereof, to a patient in need of said method.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a thromboembolic disorder comprising\n",
            "administering a direct factor Xa inhibitor that is 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide no more than once daily for at least five consecutive days in a rapid-release tablet to a patient in need thereof, wherein the thromboembolic disorder is selected from the group consisting of pulmonary embolisms, deep vein thromboses, and stroke.\n",
            "\n",
            "==addition: XARELTO, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).\n",
            "\n",
            "==same_claims_list: [33, 40, 75, 81, 85]\n",
            "********claim: \n",
            "10. A method for preventing a disorder due to thrombus formation selected from the group consisting of myocardial infarct, unstable angina, stroke, transitory ischaemic attacks, peripheral arterial occlusive disorders, pulmonary embolisms and deep venous thromboses comprising administering an effective amount of a compound of formula:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "or a hydrate thereof, to a patient in need of said method, wherein the compound is present in an amount effective to inhibit thrombus formation.\n",
            "\n",
            "********claim: \n",
            "17. A method for treating a disorder selected from the group consisting of myocardial infarct, unstable angina, stroke, transitory ischaemic attacks, peripheral arterial occlusive disorders, pulmonary embolisms and deep venous thromboses comprising administering an effective amount of a compound of formula:\n",
            "\n",
            "\n",
            "\n",
            "\n",
            "or a hydrate thereof, to a patient in need of said method.\n",
            "\n",
            "********claim: \n",
            "1. A method of treating a thromboembolic disorder comprising\n",
            "administering a direct factor Xa inhibitor that is 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide no more than once daily for at least five consecutive days in a rapid-release tablet to a patient in need thereof, wherein the thromboembolic disorder is selected from the group consisting of pulmonary embolisms, deep vein thromboses, and stroke.\n",
            "\n",
            "********claim: \n",
            "1. A method of reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral artery disease, comprising administering to the human patient rivaroxaban and aspirin in amounts that are clinically proven effective in reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral arterial disease, wherein rivaroxaban is administered in an amount of 2.5 mg twice daily and aspirin is administered in an amount of 75-100 mg daily.\n",
            "\n",
            "********claim: \n",
            "5. A method of reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral artery disease, the method comprising administering to the human patient rivaroxaban and aspirin in amounts that are clinically proven effective in reducing the risk of myocardial infarction, stroke or cardiovascular death in a human patient with coronary artery disease and/or peripheral arterial disease, wherein the method comprises once daily administration of a first product comprising rivaroxaban and aspirin and a second product comprising rivaroxaban, and further wherein the first product comprises 2.5 mg rivaroxaban and 75-100 mg aspirin and the second product comprises 2.5 mg rivaroxaban.\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "SKlMrTtp3as1"
      },
      "source": [
        ""
      ],
      "execution_count": null,
      "outputs": []
    }
  ]
}